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Alkaloids are a large group of nitrogen containing natural products found throughout 
nature, in particular in plants, which tend to possess a variety of medical uses. These 
include pain killers such as morphine and codeine, anti-cancer agents such as vinblastine 
and camptothecin, anti-malarial drugs such as quinine, anti-microbial agents, and drugs 
that affect the cardiovascular or nervous system. The usefulness of these compounds 
make them very desirable, however their complex chemical syntheses force us to rely on 
plant-extraction to obtain the molecules of interest. This process is hindered due to low 
natural abundances and difficult separation due to other similar compounds present in the 
native plants. The synthesis of plant alkaloids in microbes would enable their rapid and 
scalable production. Microbial production has the advantages of short doubling time, 
rapid extraction of the alkaloid from the culture medium, easier isolation of the desired 
alkaloid due to the absence of similar natural products, and a lack of endogenous pathway 
regulation. 
Often times, microbial production of a modified natural product can be more 
beneficial than production of the natural product, especially when looking at therapeutic 
molecules. Modifications can lead to pharmaceuticals with improved or novel uses. In 
addition, microbially-produced modified natural products can accelerate the semi-
synthesis of known and novel drugs. Chapter 1 reports the enzymatic steps that must be 
discovered, engineered, or evolved to develop microbes to produce modified alkaloids 
that would aid in the semisynthesis of FDA-approved drugs currently on the market in the 
United States. 
 xvi 
Chapter 2 focuses on microbial production of the modified monoterpene indole 
alkaloid hydroxystrictosidine in the yeast Saccharomyces cerevisiae, which could enable 
the accelerated semisynthesis of known and novel camptothecin-derived anti-cancer 
pharmaceuticals. This chapter reports the use of a pterin-dependent mono-oxidation 
strategy for the microbial synthesis of the biogenic amines dopamine and serotonin and 
the leveraging of serotonin to produce hydroxystrictosidine. 
Improving the biosynthetic performance of microbes for the synthesis of non-
colorimetric chemicals, such as serotonin, is slow due to reliance on low-throughput 
technologies for chemical detection. Chemical biosensors, which convert chemical 
detection into a fluorescent signal, have the potential to accelerate this screening process. 
Recently, we developed G-protein-coupled receptor (GPCR)-based sensors in yeast for 
this purpose. Chapter 3 reports the engineering of a GPCR-based sensor to detect 
serotonin in the spent medium of a serotonin-producing microbe in a medium-throughput 
fashion. This work showcases the ease of generating GPCR-based chemical sensors and 
their ability to detect specific chemicals in complex aqueous solutions. Further, this work 
sets the stage for the rapid engineering of serotonin-producing microbes, which can result 
in higher yielding alkaloid-producing microbes. 
Compartmentalization of metabolic pathways into organelles of the yeast S. 
cerevisiae is a useful way to improve microbial production of chemicals. While several 
translocation tags have been used to localize proteins to various organelles, there was no 
quantitative data on their translocation efficiencies. Chapter 4, reports the quantification 
of translocation efficiencies of multiple signal tags. This work will enable metabolic 
 xvii 
engineers to rationally choose translocation tags for the compartmentalization of 
metabolic pathway enzymes and to understand the limitations of the chosen tag. 
In Chapter 5, I propose future directions related to the preceding chapters.  
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CHAPTER 1. Accelerating the Semisynthesis of Alkaloid-based 
Drugs through Metabolic Engineering 
Reprinted by permission from MacMillan Publishers Ltd.: 
Ehrenworth, A.M. and Peralta-Yahya, P. Accelerating the Semisynthesis of Alkaloid-
based Drugs through Metabolic Engineering Nature Chemical Biology 13, 249-258. 
Copyright 2017. 
1.1 Abstract 
Alkaloid-derived pharmaceuticals are commonly semisynthesized from plant-
extracted starting materials, which often limits their availability and final price. Recent 
advances in synthetic biology have enabled the introduction of complete plant pathways 
into microbes for the production of plant alkaloids. Microbial production of modified 
alkaloids has the potential to accelerate the semisynthesis of alkaloid-derived drugs by 
providing advanced intermediates that are structurally closer to the final pharmaceuticals 
and could be used as advanced intermediates for the synthesis of novel drugs. Here, we 
analyze the scientific and engineering challenges that must be overcome to generate 
microbes to produce modified plant alkaloids that can provide more suitable 
intermediates to US Food and Drug Administration–approved pharmaceuticals. We 
highlight modified alkaloids that currently could be produced by leveraging existing 
alkaloid microbial platforms with minor variations to accelerate the semisynthesis of 





Natural products are a prime source of lead compounds for use in small-molecule 
drug discovery. Indeed, of all new small-molecule-based pharmaceuticals approved 
between 1981 and 2014, 51% were based on natural products whereas 49% were 
synthetic. Of the natural product-based drugs, most were natural product-derived or 
synthetic drugs with natural product backbones, while only a small minority were natural 
products or botanical mixtures
1
. Natural product-derived pharmaceuticals are often 
semisynthesized, starting with a microbially produced or plant-extracted natural product, 
which is then chemically modified to improve therapeutic properties including 
absorption, distribution, metabolism, excretion, and toxicity (ADMET)
2
. For example, 
commercial synthesis of the anticancer drugs topotecan and irinotecan starts with plant-
extracted camptothecin, while commercial production of the anticancer drug vinorelbine 
starts from plant-extracted catharanthine
3
. Access to plant natural products for use as 
starting materials in the semisynthesis of pharmaceuticals is challenging because of the 
low levels at which these products accumulate in native plants, the long doubling times of 
plants and plant cultures, and the difficult isolation of the desired natural products from 
other metabolites with similar chemical properties
4
. Substantial efforts in plant breeding 
and plant metabolic engineering have increased the yields of pharmaceutically relevant 
plant natural products, including plant alkaloids
5-8
, which have a wide range of 
therapeutic uses from anticancer and antipsychotic agents to analgesics and antimalarials. 
Nevertheless, the lack of high-throughput plant transformation and screening 
technologies, compounded by the difficulty in overcoming endogenous plant pathway 
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regulation, makes the engineering of plants for the increased production of specific 
natural products slow moving. 
Advances in metabolic engineering and synthetic biology have enabled the 
reconstruction of plant metabolic pathways in rapidly dividing microbes (0.5–3 h 
doubling time) such as Escherichia coli and Saccharomyces cerevisiae. The reduced cost 
of DNA synthesis and sequencing
9
, together with the availability of more efficient DNA 
assembly technologies
10
, has made the engineering of microbes for the low-level 
production of plant natural products routine, at least for compounds for which the 
biosynthetic enzymes are known
11
. The appeal of using microbes for the production of 
plant natural products includes the simplified purification process—no similar 
metabolites are endogenously produced by the microbe—and the sidestepping of native 
plant pathway regulation, which enable overproduction of the desired natural product or 
intermediate thereof. The vision for engineering microbes to produce plant natural 
products is to provide greater access to natural products or natural product intermediates 
for use in the semisynthesis of final therapeutics. The most successful realization of this 
vision has been the production of the antimalarial artemisinin using artemisinic acid 
produced by an engineered microbe
12
. After multiyear optimizations that resulted in 
microbial titers of 25 g/L for artemisinic acid, semisynthetic artemisinin was produced 
commercially in 2014
13
. While market demand for artemisinin has steadied lately as a 
result of changes in global malaria treatment, semisynthetic artemisinin has contributed to 





In some instances, improvements in economic value, for example, lower production 
costs, and therapeutic value, for example, access to novel structures, may be achieved by 
engineering microbes to produce alkaloids that more closely resemble current 
pharmaceuticals (Figure 1.1). Analysis of commercial alkaloid-based therapeutics shows 
that production of modified plant alkaloids that carry functional groups amenable to rapid 
chemical derivatization has the potential to enable faster semisynthesis of known or novel 
pharmaceuticals
15,16
. In the last seven years, initial efforts to leverage plants to produce 
modified alkaloids have taken place, specifically in the production of modified 
monoterpene indole alkaloids, where non-natural substrates were fed to plants to 
incorporate halogen, azido, and methyl groups in the final product or engineered 
heterologous halogenases were introduced for the addition of chlorine or bromine to the 
natural product in situ
17-20
. Nevertheless, production of modified alkaloids in planta 
suffers from the same obstacles as production of natural products in plants. 
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Figure 1.1. Microbial production of advanced intermediates for plant-alkaloid-
based pharmaceuticals. By dissecting similarities between natural products and 
current FDA-approved pharmaceuticals, microbes can be engineered for the 
production of modified alkaloids that can serve as more suitable advanced 
intermediates for the semisyntheses of known and novel pharmaceuticals when 
compared to natural products. 
Outstanding progress in plant pathway reconstruction in microbes has not majorly 
translated to the production of modified natural products in microbes. Recently, the 
majority of the work in plant pathway reconstruction in microbes has centered on 
alkaloid-based natural products. Since 2014, microbes have been engineered to produce 
over a dozen plant alkaloid natural products, including strictosidine, berberine, noscapine, 
stylopine, caffeine, cycloclavine, and various morphinans such as morphine and 
codeine
20-36
. In the same time period, microbes have been engineered to produce at least 
six modified plant alkaloids, including N-methylcheilanthifoline, 1-hydroxycanadine, 10-
hydroxystrictosidine, and current semisynthetic opioids such as hydrocodone
23,29,30,34,35,37
. 
In this chapter, we analyze how structurally far microbially produced plant alkaloids 
are from the closest US Food and Drug Administration (FDA)-approved pharmaceuticals 
and the challenges that must be overcome to engineer microbes to produce modified plant 
alkaloids that more closely resemble final pharmaceuticals (Table 1-1). Specifically, we 
focus on production in E. coli and S. cerevisiae, as these platforms have been leveraged 
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for the biosynthesis of complex plant alkaloids. We define a 'modified alkaloid' as a 
natural product alkaloid that has additional functional groups (for example, hydroxyl or 
halogen groups) or an unnatural alkaloid generated using promiscuous enzymes to 
achieve, for example, a different stereochemistry. As the microbial production of plant 
alkaloids has centered on phenylalanine- and tyrosine- or tryptophan-derived alkaloids, 
these are the major alkaloid classes covered in this chapter (Figure 1.2, Figure 1.3). 
Furthermore, we focus on the alkaloid subclasses that result in chemical cores used in 
FDA-approved pharmaceuticals. We analyze the enzymatic steps that must be 
discovered, engineered, or evolved to develop microbes to produce alkaloids that would 
aid in the semisynthesis of FDA-approved non-peptide small-molecule drugs currently on 
the market in the United States. We do not include in our analysis commonly used 
supplements without FDA approval (for example, melatonin and yohimbine), compounds 
with reported medical activities or that are currently only in clinical trials (for example, 
norcoclaurine and berberine), drugs only approved outside the United States (for 
example, noscapine), or drugs with discontinued marketing (for example, tubocurarine) 
(Drugs@FDA, https://www.accessdata.fda.gov/scripts/cder/daf/)
38
. This chapter strives to 
provide a roadmap for the enzymatic steps that would need to be discovered or 




Table 1-1. FDA approved drugs mentioned in this chapter with chemical structures and selected uses, listed by class. 
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Table 1-1 (continued) 
Drug Name Alkaloid Class Structure Uses/Treatments 











Table 1-1 (continued) 
Drug Name Alkaloid Class Structure Uses/Treatments 
Vincristine
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Listed on the WHO Model List of Essential Medicines 
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Figure 1.2. Phenylalanine- and tyrosine-derived pharmaceuticals. Representative 
phenylalanine- and tyrosine-derived FDA-approved alkaloid-based pharmaceuticals 
and key biosynthetic intermediates discussed in this chapter. 
 
Figure 1.3. Tryptophan-derived pharmaceuticals. Representative tryptophan-
derived FDA-approved alkaloid-based pharmaceuticals and key biosynthetic 
intermediates discussed in this chapter. 
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1.3 Phenylalanine- and Tyrosine-derived Alkaloid-based Pharmaceuticals 
1.3.1 Phenylethylamines 
Decarboxylation of phenylalanine and tyrosine results in phenylethylamine and 
tyramine, respectively (Figure 1.2). There are over 30 derivatives of phenylethylamine 
and tyramine among FDA-approved drugs, including epinephrine, used in the emergency 
treatment of anaphylaxis; formoterol, used for the treatment of asthma; and phenelzine, 
used to treat depression. Phenylethylamines, such as dopamine (Figure 1.2), are often 
microbially produced as precursors or intermediates to more complex plant 
alkaloids
20,30,32,37
. Industrially, however, yeast is used to produce the amphetamine-
derived drugs pseudoephedrine (Figure 1.2) and ephedrine, which contain a methyl group 
adjacent to the nitrogen, by feeding yeast benzaldehyde to produce phenylacetylcarbinol, 
which is then chemically converted to the final products
39
. Biosynthetic production of 
phenylethylamine-derived pharmaceuticals would involve enzyme discovery and/or 
engineering as has previously been proposed for amphetamine-derived pharmaceuticals
39
. 
1.3.2 Tetrahydroisoquinoline Alkaloids 
Condensation of phenylethylamine with an aldehyde via a Pictet–Spengler reaction 
results in tetrahydroisoquinoline alkaloids. The four tetrahydroisoquinoline-derived FDA-
approved pharmaceuticals are trabectedin, used to treat soft tissue sarcomas; the 
antihelmitic praziquantel; tetrabenazine, used to treat Huntington's disease symptoms; 
and solifenacin (Figure 1.2), used to treat overactive bladder. Trabectedin is obtained via 







 are sold as racemates, and biological production of 
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intermediates may not be justifiable. Solifenacin, however, is a single stereoisomer for 
which the specificity of enzymes could be leveraged. A key intermediate in the synthesis 
of solifenacin is (1S)-phenyl-tetrahydroisoquinoline (Figure 1.4a), which is produced 
industrially in three chemical steps, including a chiral resolution step in which >50% of 
the material is discarded
43
. Biologically, (1S)-phenyl-tetrahydroisoquinoline could be 
generated stereospecifically via enzymatic coupling of phenylethylamine and 
benzaldehyde using the Pictet–Spenglerase norcoclaurine synthase (NCS). Wild-type 
NCS condenses dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) to form (S)-
norcoclaurine, but it does not condense phenylethylamine with 4-HPAA or dopamine 
with benzaldehyde
44
. Engineering NCS to accept the substrates needed to generate (1S)-
phenyl-tetrahydroisoquinoline has the potential to accelerate the commercial synthesis of 
solifenacin (Figure 1.4a). 
 25 
 
Figure 1.4. Proposed semisyntheses of benzylisoquinoline alkaloid-derived FDA-
approved pharmaceuticals. Yellow box, microbe; blue, enzymes to be engineered, 
elucidated, or optimized and newly proposed semisynthetic intermediates; red, 
chemical modifications. (a) Proposed semisynthesis of solifenacin. Glucose and 
benzaldehyde can be fed to a microbe expressing an engineered norcoclaurine 
synthase (NCS) to produce (1S)-phenyl-tetrahydroisoquinoline, which can be 
converted to solifenacin in two chemical steps
43
. (b) Proposed semisynthesis of 
galantamine. Norcraugsodine can be fed to a microbe expressing noroxomaritidine 
reductase (NR), norbelladine 4′-O-methyltransferase (N4OMT), and CYP96T1 to 
produce N-demethylnarwedine, which can be converted to galantamine via N-
methylation and reduction. (c) Proposed semisynthesis of cisatracurium. Existing 
(R,S)-norlaudanosoline-producing microbes expressing G. flavum O-
methyltransferase (GFLOMT2) could produce (R)-tetrahydropapaverine, which 
can be converted to cisatracurium using established synthetic routes
53
. 
1.3.3 Amaryllidaceae Alkaloids 
Condensation of tyramine with 3,4-dihydroxybenzaldehyde followed by reduction 
results in norbelladine (Figure 1.2), the common precursor to amaryllidaceae alkaloids. 
The natural product galantamine (Figure 1.2), used for the treatment of Alzheimer's 
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disease, is the only FDA-approved amaryllidaceae-based pharmaceutical. Galantamine is 
produced by various plant species, Galanthus sp. in particular, and plant-extracted 
galantamine is used commercially
45
. The low levels of galantamine accumulation in 
natural sources and high cost of isolating it ($50,000/kg) have resulted in substantial 
efforts toward its chemical synthesis
46
. The crux in the chemical synthesis of galantamine 
is introduction of the correct stereochemistry at the tricyclic benzofuran core
47
, which in 
nature is installed by the phenol-phenol coupling enzyme CYP96T1 that produces N-
demethylnarwedine as a minor product
48
 (Figure 1.4b). N-Demethylnarwedine can be 
chemically converted to the final galantamine via reduction of the conjugated ketone into 
a conjugated alcohol and methylation of the only amine. Microbial production of N-








feeding it chemically synthesized norcraugsodine (Figure 1.4b), which is one chemical 
step from tyramine and 3,4-dihydroxybenzaldehyde
50
. Improving the product specificity 
of CYP96T1 so that this enzyme preferentially produces N-demethylnarwedine would 
further increase the production of galantamine. 
1.3.4 Phenylethylisoquinoline Alkaloids 
Hydroxylation of tyrosine to L-3,4-dihydroxyphenylalanine (DOPA) followed by 
decarboxylation results in dopamine (Figure 1.2). Condensation of dopamine and 4-
hydroxydihydrocinnamaldehyde generates the scaffold of phenylethylisoquinoline 
alkaloids
51
. Colchicine (Figure 1.2), the only approved phenylethylisoquinoline-based 
pharmaceutical, is used in the treatment of acute gout and is obtained from Gloriosa 
superba for commercial production
51
. The colchicine biosynthetic pathway from 
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dopamine and 4-hydroxydihydrocinnamaldehyde is not known, and the only elucidated 
step is the P450-dependent oxidation of autumnaline (Figure 1.2) to isoandrocymbine
52
. 
Genome sequencing of G. superba would aid in the discovery of colchicine biosynthetic 
enzymes, which catalyze steps including oxidation, ring formation and cleavage, 
methylation and demethylation, and amide hydrolysis and formation. 
1.3.5 Benzylisoquinoline Alkaloids 
Condensation of dopamine and 4-HPAA results in (S)-norcoclaurine, which is 
eventually converted to (S)-reticuline, the common precursor to all benzylisoquinoline 
alkaloids (BIAs) (Figure 1.2). The engineering of microbes for the production of BIAs 
has been extremely successful in the last eight years
7,11
. Briefly, simple BIAs, including 
norcoclaurine, norlaudanosoline, and reticuline, have been microbially produced from 
simple sugars, while more complex BIAs, including morphine, magnoflorine, canadine, 
and noscapine, have been produced from simple sugars or advanced intermediates. 
Dimerization of two simple BIAs via one or two ether linkages results in 
bisbenzylisoquinoline alkaloids (BBIAs). Synthetic BBIA cores, however, are connected 
via a polymethylene chain
51
. Three synthetic BBIA-based drugs, atracurium, 
mivacurium, and cisatracurium (Figure 1.2), have been approved as muscle relaxants. 
Atracurium, which is on the World Health Organization (WHO) Model List of Essential 
Medicines (http://www.who.int/medicines/publications/essentialmedicines/en/), is an 
isomeric mixture, while cisatracurium, the R-cis, R-cis isomer of atracurium, has superior 
pharmacodynamics and fewer side effects in comparison to atracurium
53
. Cisatracurium 
is chemically synthesized in two steps from (R)-tetrahydropapaverine (Figure 1.4c)
53
, 




. Although (S)-tetrahydropapaverine is the natural product, 
non-natural (R)-tetrahydropapaverine could be produced from (R)-norlaudanosoline 
starting from glucose by engineering a single enzyme (Figure 1.4c). Racemic (R,S)-
norlaudanosoline has been produced in E. coli via spontaneous Pictet–Spengler 
condensation of dopamine and 3,4-dihydroxyphenylacetaldehyde starting from supplied 
glucose
36
, and many BIA O-methyltransferases accept both the R and R,S forms of their 
respective substrates
54, 55
. Indeed, feeding (R,S)-norlaudanosoline to E. coli expressing 
Glaucium flavum GFLOMT2 resulted in tetrahydropapaverine production
56
. As no 
norlaudanosoline was found after the reaction, it is hypothesized that the enzyme 
converted both R and S isomers. Analysis of this and related methyltransferases to 
understand their substrate and product specificities and improve their activity on the R 
stereoisomer should further enable the biological production of (R)-tetrahydropapaverine 
and accelerate the large-scale semisynthesis of cisatracurium. 
1.3.6 Aporphines and Morphinans 
Oxidative coupling within the scaffold of the BIA (S)-reticuline results in aporphines, 
while coupling within the scaffold of (R)-reticuline, a downstream intermediate, results in 
morphinans. The semisynthetic aporphine apomorphine has been approved for the 
treatment of Parkinson's disease and is made via chemical rearrangement of morphine
57
 
(Figure 1.2). Morphinans are a major class of alkaloid-based FDA-approved 
pharmaceuticals with 16 compounds, most of which are analgesics. Among the 16 
compounds are found the natural product morphine, four pharmaceuticals that are 
semisynthesized from morphine (including the natural product codeine; Figure 1.2), eight 




. Morphine and thebaine are currently obtained from poppy (Papaver 
somniferum and Papaver bracteatum
58
) and, while plant-extracted morphinan alkaloids 
meet current demand (United Nations International Control Board, 
http://www.incb.org/documents/Publications/AnnualReports/AR2015/English/Supp/AR1
5_Availability_E_Chapter_II.pdf), microbial production represents an alternative supply 
that is attractive because of the drawbacks associated with plant harvesting and 
unpredictable environmental factors. The natural product morphine has been microbially 
produced in yeast from thebaine or codeine
28,34
, and morphine-derived drugs have also 





, or simple carbon sources 
(hydrocodone)
29,30
. As the remaining semisynthesized morphinans (buprenorphine, 
methylnaltrexone, nalbuphine, naloxegol, naloxone, naltrexone, and oxymorphone) are 
chemically synthesized from thebaine and thebaine has been microbially made from 
simple carbon sources
29,30
, there is the possibility of an alternative microbial source for 
all the natural and semisynthetic morphinans on the market. Today, a key issue with 
microbially produced morphinan-based alkaloids is the low yields. Morphine has been 
microbially produced from thebaine at 1.5% molar yield, while thebaine has been 
produced at <0.001% molar yield from glucose
29,34
. 
An as yet unexplored idea has been to provide late intermediates for the 
semisynthesis of fully synthetic morphinan-derived drugs. Levorphanol (Figure 1.5a) is 
chemically synthesized in eight steps from cyclohexanone
58
. The closest natural product 
to levorphanol is salutaridinol, an intermediate in the thebaine–morphine pathway (Figure 
1.5a). Salutaridinol contains multiple hydroxyls, methoxys, and alkenes, and it could be 
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demethylated and chemically reduced to form levorphanol or only partially chemically 
modified to generate levorphanol derivatives. Butorphanol (Figure 1.5a) is chemically 
synthesized in 13 steps from 7-methoxy-3,4-dihydronaphthalen-1(2H)-one via the 
intermediate 8,14-didehydro-3-methoxymorphinan (DDMM), which is produced after 
nine steps
58
. The closest natural product to DDMM is also salutaridinol (Figure 1.5a). 
Unlike DDMM, salutaridinol is N-methylated, which would hinder the current strategy of 
chemically adding the cyclobutylmethyl group found in butorphanol. As salutaridine 
synthase has shown activity toward N-desmethylated (R)-norreticuline to produce 
norsalutaridine
59
, it is likely that either the previously elucidated salutaridine reductase or 
novel homologs could produce N-desmethylated norsalutaridinol (Figure 1.5a). 
Norsalutaridinol could be demethylated and reduced chemically to form DDMM or only 
partially modified to generate butorphanol derivatives. 
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Figure 1.5. Proposed semisyntheses of morphinan- and pyrroloquinoline-derived 
FDA-approved pharmaceuticals. Yellow box, microbe; blue, enzymes to be 
engineered, elucidated, or optimized and newly proposed semisynthetic 
intermediates; red, chemical modifications. (a) Proposed semisynthesis of 
levorphanol and butorphanol. Top, existing microbial strains produce salutaridinol, 
which requires chemical demethylation and reduction to produce levorphanol. 
Bottom, existing microbial strains expressing salutaridine synthase (SalS) and 
homologs of salutaridine reductase (SalR) could produce norsalutaridinol, which 
can be converted to 8,14-didehydro-3-methoxymorphinan (DDMM) via chemical 
demethylation and reduction steps. DDMM is a late intermediate in the chemical 
synthesis of butorphanol
58
. (b) Proposed semisynthesis of irinotecan and topotecan. 
The modified alkaloid 10-hydroxystrictosidine has been produced in yeast
37
. 
Camptothecin pathway enzymes from strictosidine need to be elucidated and their 
promiscuity assessed to produce 10-hydroxycamptothecin, which can be dropped 
into existing commercial syntheses of irinotecan and topotecan, which currently rely 
on camptothecin
76,77
. Dotted arrows, unknown enzymes. 
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1.4 Tryptophan-derived Alkaloid-based Pharmaceuticals 
1.4.1 Tryptamines and β-Carbolines 
Decarboxylation of tryptophan results in tryptamine, and eight simple tryptamine 
derivatives including six 'triptans' such as sumatriptan and rizatriptan are on the market 
(Figure 1.3). Tryptamine derivatives, such as serotonin, and tryptamine itself are common 
intermediates in microbial productions
21,37
, and some have also been produced as end 
products
60,61
. However, simple tryptamine derivatives can be efficiently produced 
chemically
62
. Condensation of tryptamine and aldehydes results in β-carbolines. Tadalafil 
(Cialis®; Figure 1.3), a vasodilator used for male erectile dysfunction, is the only 
approved β-carboline drug on the market. The key structural features of tadalafil are the 
cis arrangements of the benzodioxole and piperazinedione moieties of the β-carboline 
scaffold. Although enzymes could provide the desired enantiomeric selectivity, the 
commercial synthesis of tadalafil is three steps starting from commercially available 
starting materials and leverages the fact that the desired cis isomer precipitates out of the 
reaction while the trans isomer stays in solution
63
. 
1.4.2 Monoterpene Indole Alkaloids 
Condensation of tryptamine with the monoterpene secologanin generates (S)-
strictosidine, the key intermediate to monoterpene indole alkaloids (MIAs)
64
 (Figure 1.3). 
The four FDA-approved MIA-based pharmaceuticals on the market comprise the 
antihypertensive agent reserpine and the anticancer drugs vinorelbine, vinblastine, and 
vincristine (Figure 1.3). Reserpine is a natural product and is extracted from Rauwolfia 
vomitoria for commercial production
65
. The biosynthetic pathway for reserpine is yet to 
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be elucidated, and an intriguing feature of this chemical is the (R) stereochemistry at the 
C3 position, which hints that (R)-strictosidine might be the key biosynthetic precursor to 
reserpine rather than (S)-strictosidine
51
. Vinorelbine is a semisynthetic drug made in two 
steps from anhydrovinblastine obtained chemically or enzymatically from plant-extracted 
catharanthine and vindoline
51
. Similar to vinorelbine, vinblastine and vincristine are also 
bisindoles formed via the condensation of catharanthine and vindoline, although they are 
natural products. 
Unlike the microbial production of morphinans, in which microbes are now available 
for the production of complex morphinan-derived alkaloids, the engineering of microbes 
for the production of complex bisindole MIAs has lagged behind, mainly because of 
incomplete elucidation of MIA biosynthetic pathways. Specifically, microbial bisindole 
MIA production has been limited to early intermediates, up to strictosidine
21
, or 
conversion of later intermediates such as tabersonine into vindoline
31
. This is due to the 
limited pathway knowledge beyond strictosidine other than (i) strictosidine-β-
glucosidase, which converts strictosidine to a common intermediate that spontaneously 
converts to cathenamine in vitro; (ii) the enzymes converting tabernosine to vindoline; 
and (iii) α-3,4-anhydrovinblastine synthase, which dimerizes vindoline and catharanthine 
to form anhydrovinblastine
64
. As a point of reference, only in 2014 was the complete 
upstream secologanin biosynthetic pathway elucidated
66
. Just one year later, the 
secologanin pathway was refactored in yeast for the de novo production of strictosidine
21
, 
underscoring the idea that the engineering of microbes for the production of MIAs is 
limited by biosynthetic pathway discovery. MIA pathway elucidation will open the door 
to the engineering of microbes for the production of naturally occurring and modified 
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 knowledge, we can really start to 
utilize microbes that produce key intermediates or feed microbes key intermediates to 
screen for potential pathway enzymes
20,29,70
. 
1.4.3 Quinoline Alkaloids 
Rearrangement of the indole ring in (S)-strictosidine to a quinoline ring results in 
quinoline alkaloids. The natural product diastereomers quinine, used to treat malaria, and 
quinidine, used to treat arrhythmia, are the only two MIA-derived quinolines approved on 
the market (Figure 1.3). Cinchona bark is the sole commercial source of these 
compounds, with 300–500 tons of alkaloids extracted per year, ~40% of which go to 
pharmaceutical production
71
. Chemical synthesis of quinine has a long history, with the 
first stereoselective total synthesis of quinine accomplished in 2001, involving 13 steps 
and giving <10% yield
72
. Although plant-extracted quinine is sufficient for 
pharmaceutical production
71
, quinine and quinidine production in Cinchona trees takes 
years of growth and leads to destructive harvesting of the trees
51
. The lack of biosynthetic 
pathway knowledge for quinine or quinidine hinders the reconstruction of these pathways 
in microbes. Today, only one of the final enzymes in the quinoline biosynthetic pathway, 
cinchoninone:NADPH oxidoreductase, has been isolated and characterized
73
, yet its 
protein sequence is unknown. 
1.4.4 Pyrroloquinoline Alkaloids 
A different rearrangement of (S)-strictosidine results in pyrroloquinoline alkaloids, 
which include the natural product, and topoisomerase I inhibitor, camptothecin (Figure 




camptothecin derivatives, the anticancer agents irinotecan and topotecan (Figure 1.3), are 
the only approved pyrroloquinoline-based drugs on the market, while three other 
camptothecin derivatives are in active clinical trials or development 
(https://clinicaltrials.gov/ and http://adisinsight.springer.com/)
38
. Despite several reports 
on the total synthesis of camptothecin and its derivatives
74,75
, irinotecan and topotecan are 
semisynthesized from plant-extracted camptothecin for commercial use
76,77
. Today, plant-
extracted camptothecin (600 kg/year) does not meet the demand for the synthesis of 
camptothecin derivatives (3,000 kg/year)
78
, which leads to destructive harvesting of 
Camptotheca acuminata and Nothapodytes foetida trees
79
, potentially restricting the 
future supply of camptothecin-derived drugs. The slow growth of the woody trees C. 
acuminata and N. foetida has led to the engineering of hairy-root cultures of these and 
other plants that accumulate camptothecin, such as Ophirriza pumila
80,81
. As the 
camptothecin biosynthetic pathway has not been fully elucidated, plant engineering 
efforts rely solely on upregulation of early MIA pathway enzymes
80
. Knowledge of the 
camptothecin biosynthetic pathway from strictosidine would not only aid plant 
engineering efforts for high-level camptothecin production but also enable the 
engineering of microbial platforms for the production of camptothecin. After lactam 
formation of strictosidine, or strictosidinic acid, to form strictosamide, the proposed 
camptothecin biosynthetic pathway consists of multiple oxidations and reductions, a 
dehydration, and a deglycosylation and includes an unknown conversion of the β-
carboline to the pyrroloquinoline scaffold
51,82
. A currently accessible strategy for 
pathway elucidation is to engineer a microbe for the production of a late intermediate, 




biosynthetic pathway knowledge would allow the bioproduction of camptothecin, both 
irinotecan and topotecan are modified at the 10′ position by introduction of a hydroxyl 
group or a bipiperidine moiety via an ester bond, and their semisyntheses proceed 
through a 10-hydroxycamptothecin intermediate (Figure 1.5b)
76,77
. Therefore, microbial 
production of 10-hydroxycamptothecin instead of camptothecin may be more appealing 
for the semisynthesis of camptothecin derivatives (Figure 1.5b). Indeed, we have recently 
demonstrated that production of modified MIAs such as 10-hydroxystrictosidine (Figure 
1.5b) is possible by using plant, mammalian, fungal, and bacterial enzymes expressed in 
S. cerevisiae
37
. Given that 10-hydroxylated MIAs have been produced in Catharanthus 
roseus hairy-root culture fed with serotonin
83
, it is likely that enzymes downstream in the 
camptothecin pathway would accept 10-hydroxystrictosidine to generate 10-
hydroxycamptothecin in microbes as well. 
1.4.5 Ergot Alkaloids 
Ergot alkaloids are derived from the combination of tryptophan and dimethylallyl 
pyrophosphate (Figure 1.3). While mainly of fungal origin, ergot alkaloids are often 
found in fungi that infect grains or in fungi-associated plants
84
 and are thus included in 
this chapter. There are currently six approved ergot alkaloids on the market, including 
treatments for parkinsonian syndrome and vasoconstrictors. The four ergopeptides 
(ergotamine (Figure 1.3), dihydroergotamine, ergoloid mesylate, and bromocriptine) are 
synthesized from lysergic acid and synthetic peptides
85
, although they can be obtained by 
other production or isolation routes as well. The two ergoamides cabergoline and 
methylergonovine (Figure 1.3) can also be synthesized from lysergic acid. Today, most 
lysergic acid is semisynthesized from paspalic acid (Figure 1.6) or lysergic acid 
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hydroxyethylamide obtained from Claviceps fermentation broth
85
. As the compounds 
isolated from ergot fermentation can be impure because of the abundance of similar 
metabolites, heterologous production of lysergic acid in a non-ergot-producing microbe 
could be beneficial for the production of ergot-based pharmaceuticals. Conversion of 
tryptophan and dimethylallyl pyrophosphate to lysergic acid can be catalyzed by eight 
enzymes (Figure 1.6). Although heterologous microbial production of lysergic acid in a 
non-ergot-producing microbe has not been shown, all enzymes in this pathway are 
known. The early ergot intermediate chanoclavine-I (Figure 1.6) has been produced from 
glucose in S. cerevisiae
33
 and from sucrose in Aspergillus nidulans
86
 and has been 
converted in vitro to chanoclavine-I aldehyde
87
, and subsequently to agroclavine
88
 
(Figure 1.6). Agroclavine has also been produced through reprogramming of the 
fumigaclavine ergot producer Aspergillus fumigatus
89
. Expression of clavine oxidase 
(CloA) in the reprogrammed A. fumigatus resulted in production of lysergic acid, 
although the final conversion of paspalic acid to lysergic acid may be catalyzed by 
another isomerase or be completed spontaneously
84
. Microbially produced lysergic acid 
could be used in the semisynthesis of current drugs or could be microbially converted to 
ergoamides and ergopeptides via two non-ribosomal peptide synthases and, in the case of 
ergopeptides, a dioxygenase. 
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Figure 1.6. Proposed microbial production of lysergic acid for the semisynthesis of 
ergot alkaloids. Yellow box, non-ergot-producing microbe; red arrow, chemical 
modification to reach ergot alkaloids. The early ergot intermediate chanoclavine-I 
has been produced in S. cerevisiae and A. nidulans and, although microbial 
conversion of chanoclavine-I to lysergic acid has not been shown in a non-ergot-
producing microbe, all enzymes in this pathway are known. Microbially produced 
lysergic acid can be used in current chemical syntheses of ergoamides and 
ergopeptides. Abbreviations: DmaW, tryptophan dimethylallyltransferase; 
DMAPP, dimethylallylpyrophosphate; EasF, 4-dimethylallyltryptophan N-
methyltransferase; EasE, FAD-linked oxidoreductase; EasC, catalase; FgaDH, 
chanoclavine-I dehydrogenase; EasA_Nl, chanoclavine-I aldehyde reductase from 
Neotyphodium lolii; EasG, agroclavine dehydrogenase; CloA, clavine oxidase. 
1.5 Enzymatic Production of Modified Alkaloids 
Many natural product derivatives are obtained through chemical modifications; 
however, engineering microbes to produce modified alkaloids has the potential to supply 
more advanced intermediates for the semisynthesis of natural product-derived 
pharmaceuticals, to supply alternative production sources for currently semisynthesized 
drugs, or to speed up the generation of novel drug analogs
15,16
. Taking advantage of 
biosynthetic enzyme promiscuity and removal of plant pathway regulation, modified 
BIAs have been produced microbially
23,34,35
. Furthermore, the broad substrate specificity 
of the BIA Pictet–Spenglerase NCS has enabled the condensation of substrates carrying 
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fluoride, methyl, and methoxy modifications as well as the condensation of drastically 
different analogs, such as thiophene
44
. Substantial headway has also been made in the 
production of modified MIAs, including the incorporation of a hydroxyl group in 
strictosidine in yeast
37
 and halogens (chlorine and bromine) in C. roseus root cultures
17,18
. 
Hydroxyls and halogens, as well as azido and methyl groups, are accepted by 
downstream enzymes in C. roseus root and cell cultures to produce modified complex 
MIAs, including modified ajmalicine, serpentine, tabersonine, and vindoline
17,18,19,83
. As 
with NCS, strictosidine synthase (the MIA Pictet–Spenglerase) has been shown to 
promiscuously accept a range of unnatural substrates, including benzofuran, 
benzothiophene, and aza-indole tryptamine derivatives
90,91
, and enzymes in the upstream 
iridoid pathway exhibit promiscuity as well
92,93
. Enzymes have also been engineered to 
accept modified substrates for modified MIA production4. For example, tryptophan 





able to produce both chlorinated and brominated compounds, such as 7-chlorotryptamine 
and 5-bromotryptophan. Enzymatic halogenation is not only more environmentally 
friendly than chemical halogenation but also enables the incorporation of halogens at key 
chemical positions, which may be difficult using chemical methods
95
. Strategic 
incorporation of modifications such as hydroxyls, alkenes, or halogens can facilitate 
regiospecific chemical reactions without major concerns of cross-reactivity. An example 
of this can be seen in the semisynthesis of MIA analogs wherein chlorinated or 
brominated tryptamines were either fed to or formed in situ in C. roseus hairy-root 





Although fluorinated natural products remain rare, fluorinated pharmaceuticals are 
highly represented on the market (~20.25%)
95
. Fluorine modifications can improve many 
drug characteristics, including potency and ADMET properties
97
. While multiple classes 
of halogenases exist
95
, fluorinases are still difficult to identify, with only one enzyme 
currently known: 5′-fluoro-5′-deoxyadenosine synthase, which converts S-
adenosylmethionine (SAM) and a fluoride ion into 5′fluoro-5′deoxyadenosine and L-
methionine, a reaction in the biosynthesis of fluoroacetate
98
. Fluoroacetate is a promising 
building block in fluorinated compounds such as polyketides
99,100
. Given the 
pharmaceutical importance of fluorine modifications and the ability of downstream 
alkaloid enzymes to accept fluorinated intermediates
83
, one can envision discovery of 
new fluorinases and/or engineering of other halogenases for the fluorination of plant 
alkaloids. 
1.6 Conclusion 
Microbial production of strategically modified plant alkaloids has the capability to 
accelerate the production and reduce the cost of FDA-approved drugs and open the door 
for the rapid generation of potentially new pharmaceuticals. Although many alkaloids on 
the market are natural products, natural product-derived alkaloids such as topotecan and 
irinotecan often have improved therapeutic properties, including better solubility, 
chemical stability, metabolic stability, and potency
2
. The limited presence of natural 
product derivatives among alkaloid-based pharmaceuticals may stem from (i) the 
difficulty of generating derivatives starting with the plant-extracted terminal natural 
product, which is often highly hydroxylated, making it difficult to selectively modify 
specific positions in the molecule; (ii) the limited availability of natural product starting 
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material for chemical modification; or (iii) the expensiveness of total synthesis of natural 
product-like compounds. Although alkaloid derivatives are now obtained via chemical 
modifications, engineering microbes to produce modified alkaloids has the potential to 
supply more advanced intermediates to aid the semisynthesis of alkaloid-derived 
pharmaceuticals or enable the generation of novel drug analogs
15,16
. 
With the advent of synthetic biology technologies, microbes are poised to start 
generating a number of modified alkaloids in coming years because of their fast doubling 
times, their efficient uptake of modified substrates, and the ease of downstream 
processing in isolating the plant-derived products due to the lack of similar metabolites in 
the microbial medium. Furthermore, reconstruction of heterologous plant pathways in 
microbes has the advantage of bypassing endogenous plant regulation and the ability to 
rapidly mix and match enzymes from different species. A key challenge that remains in 
achieving the vision of high-level microbial production of modified plant alkaloids is 
biosynthetic pathway elucidation. This is exemplified by the fact that, for products where 
the biosynthetic pathway has been elucidated, an increasing number of works use 
promiscuous or engineered enzymes to incorporate useful chemical handles that would 
allow synthesis or semisynthesis of known and novel pharmaceuticals. This is seen in the 
numerous works published on microbial BIA production, which have culminated in the 
microbial production of final pharmaceuticals, current semisynthetic intermediates, and 
modified natural products. Yet, when the pathways are unknown, microbial engineering 
of modified alkaloids is severely limited, as can be seen in the lack of progress for MIAs 
(which has thus far culminated in early intermediates in the natural product pathways) 
and other alkaloid classes that have little to no microbial reconstruction work completed. 
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However, notable work focused on modifications of these early intermediates provides 
optimism for the rapid production of useful modified alkaloids and/or final 
pharmaceuticals upon further pathway elucidation. 
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CHAPTER 2. Pterin-dependent Mono-oxidation for the Microbial 
Synthesis of a Modified Monoterpene Indole Alkaloid 
Reproduced with permission from: 
Ehrenworth, A.M., Sarria, S., and Peralta-Yahya, P. Pterin-dependent Mono-oxidation for 
the Microbial Synthesis of a Modified Monoterpene Indole Alkaloid ACS Synthetic 
Biology 4, 1295-1307. Copyright 2015 American Chemical Society. 
2.1 Abstract 
Monoterpene indole alkaloids (MIAs) have important therapeutic value, including as 
anticancer and antimalarial agents. Because of their chemical complexity, therapeutic 
MIAs, or advanced intermediates thereof, are often isolated from the native plants. The 
microbial synthesis of MIAs would allow for the rapid and scalable production of 
complex MIAs and MIA analogues for therapeutic use. Here, we produce the modified 
MIA hydroxystrictosidine from glucose and the monoterpene secologanin via a pterin-
dependent mono-oxidation strategy. Specifically, we engineered the yeast Saccharomyces 
cerevisiae for the high-level synthesis of tetrahydrobiopterin to mono-oxidize tryptophan 
to 5-hydroxytryptophan, which, after decarboxylation to serotonin, is coupled to 
exogenously fed secologanin to produce 10-hydroxystrictosidine in an eight-enzyme 
pathway. We selected hydroxystrictosidine as our synthetic target because hydroxylation 
at the 10′ position of the alkaloid core strictosidine provides a chemical handle for the 
future chemical semisynthesis of therapeutics. We show the generality of the pterin-
dependent mono-oxidation strategy for alkaloid synthesis by hydroxylating tyrosine to L-
DOPA—a key intermediate in benzylisoquinoline alkaloid (BIA) biosynthesis—and, 
thereafter, further converting it to dopamine. Together, these results present the first 
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microbial synthesis of a modified alkaloid, the first production of tetrahydrobiopterin in 
yeast, and the first use of a pterin-dependent mono-oxidation strategy for the synthesis of 
L-DOPA. This work opens the door to the scalable production of MIAs as well as the 
production of modified MIAs to serve as late intermediates in the semisynthesis of 
known and novel therapeutics. Further, the microbial strains in this work can be used as 
plant pathway discovery tools to elucidate known MIA biosynthetic pathways or to 
identify pathways leading to novel MIAs. 
2.2 Introduction 
Alkaloids are the largest group of nitrogen-containing secondary metabolites, with 
more than 20 000 structures
1
, are present in roughly 20% of plant species
2
, and are 
important because of their medicinal use
3
. Of particular importance are monoterpene 
indole alkaloids (MIAs), which include anticancer agents such as camptothecin (1) and 
vinblastine (2), antimalarial agents such as quinine, and antiarrhythmic agents such as 
ajmalicine. Another important alkaloid family is benzylisoquinoline alkaloids (BIAs), 
which include the antibiotic berberine (3) and the analgesic morphine (4)
4
. Due to their 
chemical complexity, alkaloids often require multistep chemical syntheses, which, 
coupled with the necessity of enantiopure material, make them a challenging synthetic 
target
5-8
. Therefore, medically important alkaloids, or advanced intermediates thereof, are 
frequently isolated directly from the native plants
5,7,9
. Although effective, isolation of 
alkaloids from plants is often limited by their low accumulation in plant tissue and their 
difficult separation from other natural products, thus resulting in the high cost of alkaloid-
derived pharmaceuticals, especially those based on MIAs
5,7
. Via plant breeding and, more 




. Further, plants have been engineered to produce halogenated MIAs, 
with potentially higher bioactivity, which can serve as late intermediates in the 
semisynthesis of other alkaloids
14-16
. Nevertheless, limited understanding of plant 
secondary metabolite regulation and slow plant growth rate cloud the future of 
engineering plants to overproduce alkaloids
2,5,7
. These limitations result in the 
underrepresentation of alkaloid-derived compounds in pharmaceutical drug screenings
17
. 
The synthesis of plant alkaloids in microbes would enable the rapid and scalable 
production of known alkaloids and open the door to the biosynthesis of novel alkaloids 
using engineered enzymes or combinatorial enzyme assembly. Plant alkaloid production 
in microbes has the advantages of short doubling time, rapid extraction of the alkaloid 
from the culture medium, easier isolation of the desired alkaloid due to the absence of 
similar natural products, and a lack of endogenous pathway regulation, which allows for 
deregulation of alkaloid biosynthesis. 
Many alkaloids are obtained via the hydroxylation and decarboxylation of amino 
acids
18
. Specifically, BIAs are derived from tyrosine (5) and MIAs are derived from 
tryptophan (6). In the last 10 years, full elucidation of many BIA biosynthetic pathways
4
, 
in conjunction with advances in synthetic biology, have enabled the reconstruction of 
BIA pathways in both Escherichia coli and Saccharomyces cerevisiae
19-25
. Although 
MIA biosynthetic pathways have been extensively engineered in planta
14-15
, the 
engineering of MIA alkaloids in microbes has been limited. A major problem in 
engineering microbes for the synthesis of plant alkaloids is the amino acid hydroxylation 
step. Tyrosinase, the most common enzyme used to hydroxylate tyrosine, not only 
oxidizes tyrosine into L-3,4-dihydroxyphenylalanine (L-DOPA, 7), but its o-diphenolase 
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activity also results in further oxidation of L-DOPA to L-dopaquinone, a melanin 
precursor
26-28
, thus reducing the availability of L-DOPA for alkaloid production. 
Nevertheless, tyrosinase has been used to produce the BIA reticuline from glycerol
21,25
. 
Recently, a P450 enzyme from beet was engineered for reduced o-diphenolase activity to 
increase the specificity of tyrosine hydroxylation to L-DOPA
29
. There is no equivalent to 
tyrosinase for tryptophan hydroxylation. To circumvent this problem, microbial synthesis 
of 5-hydroxytryptophan (8) has been achieved by indole hydroxylation followed by 
coupling to serine
30
 or using an engineered phenylalanine hydroxylase with changed 
substrate specificity
31
. Hydroxytrytophan has not been converted to serotonin (9) or to 
MIAs microbially from glucose. Specific mono-oxygenases for tyrosine and tryptophan 
exist in higher eukaryotes; however, they require the pterin cofactor tetrahydrobiopterin 
(BH4, 10), which is not present in E. coli or S. cerevisiae. 
We hypothesized that a pterin-dependent oxidation strategy to specifically mono-
oxidize tyrosine or tryptophan would provide an alternative route for MIA and BIA 
biosynthesis (Figure 2.2). The difficulty in this strategy is that neither E. coli nor S. 
cerevisiae endogenously produces BH4, which is necessary for the activity of mono-
oxygenases found in higher eukaroytes
32,33
. Although BH4 has been previously produced 
in E. coli
34
, it was not coupled to amino acid mono-oxidation. The endogenous E. coli 
BH4 analogue, tetrahydromonapterin (MH4), has been promiscuously used as a cofactor 





. However, MH4 does not have the correct composition or 
stereochemistry when compared to BH4 (Figure 2.1), which is likely to be accepted with 
higher efficiency by amino acid mono-oxygenases from higher eukaryotes
32,36
, such as 
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those in this study. To establish a microbial platform for the synthesis of plant alkaloids 
via the pterin-dependent mono-oxidation strategy, we engineered S. cerevisiae for BH4 
production. We selected S. cerevisiae as the microbial host because yeast, like plants, is 
eukaryotic. A yeast platform for amino acid mono-oxidation will facilitate the synthesis 
of complex plant alkaloids, as expression of downstream alkaloid pathway enzymes are 
thought to be mainly transmembrane cytochrome P450s, which are difficult to 
functionally express in bacteria such as E. coli
20,37
 without protein engineering
38-40
. In 
addition, S. cerevisiae’s robustness, tolerance to industrial conditions, including low pH 
and high sugar concentrations, and insusceptibility to phage infection make it the ideal 




Figure 2.1. Stereochemistry of pterin co-factors. Chemical structures of 
tetrahydrobiopterin (BH4), the natural amino acid mono-oxygenase co-factor, and 
tetrahydromonapterin (MH4), the BH4 analogue found in E. coli. BH4 and MH4 vary 
in stereochemistry and composition. 
Here, we report the use of a pterin-dependent mono-oxidation strategy for the 
microbial synthesis of the biogenic amines dopamine and serotonin and the leveraging of 
serotonin to produce a modified MIA. Specifically, we engineered BH4-producing yeast 
to mono-oxidize tryptophan to 5-hydroxytryptophan, which, after decarboxylation to 
serotonin, is condensed with the monoterpene secologanin (11) to produce the modified 
MIA hydroxystrictosidine (12). First, we combinatorially screened BH4 biosynthetic 
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enzymes to identify the enzyme assembly leading to the highest BH4 production. Next, 
we introduced a BH4 recycling pathway to guarantee supply of BH4 to the amino acid 
mono-oxygenases. Then, we showed that pterin-dependent oxidation of tryptophan 
followed by decarboxylation results in serotonin, a key MIA intermediate. Finally, we 
introduced the MIA biosynthetic pathway to ultimately produce hydroxystrictosidine 
from glucose and secologanin. We show the generality of the pterin-dependent mono-
oxidation strategy for the microbial synthesis of alkaloids by using a tyrosine mono-
oxygenase to convert tyrosine into L-DOPA, which is subsequently decarboxylated to 
dopamine (13), a key BIA intermediate. This is the first production of BH4 in S. 
cerevisiae and the first microbial synthesis of a modified MIA. Further, this is the first 
time that S. cerevisiae has been engineered to produce the key BIA biogenic amine, 
dopamine, and the key MIA biogenic amine, serotonin, from glucose via pterin-
dependent mono-oxidation. The microbial strains presented in this work open the door to 
the scalable production of MIAs, as well as the production of modified MIAs to serve as 
late intermediates in the semisynthesis of known and novel therapeutics. Further, the 
microbial strains in this work can be used as plant pathway discovery tools to elucidate 
known MIA biosynthetic pathways or to identify pathways leading to novel MIAs. 
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Figure 2.2. Pterin-dependent microbial synthesis of monoterpene indole alkaloids 
(MIAs) in Saccharomyces cerevisiae. General schematic of MIA and 
benzylisoquinoline alkaloid microbial synthesis via pterin-dependent mono-
oxidation. The engineered strains of S. cerevisiae presented in this work contain one 
or more of the following: (I) the BH4 biosynthetic pathway, (II) the BH4 recycling 
pathway, (III) a pterin-dependent mono-oxygenase, (IV) a decarboxylase, or (V) a 
Pictet–Spenglerase. Gray arrows represent future potential of the system. GTPCH, 
GTP cyclohydrolase; PTPS, pyruvoyl tetrahydropterin synthase; SR, sepiapterin 
reductase; PCD, pterin-4a-carbinolamine dehydratase; DHPR, dihydropteridine 
reductase; TPH, tryptophan hydroxylase; TH, tyrosine hydroxylase; DDC, 
aromatic-L-amino-acid decarboxylase; STR, strictosidine synthase. 
2.3 Results 
2.3.1 Target Choice: Hydroxystrictosidine 
While the natural branch point in MIA biosynthesis is strictosidine
44
, we pursued 
instead the biosynthesis of 10-hydroxystrictosidine, an MIA that can be produced by 
Camptotheca acuminata
45
, the major producer of the anticancer agent camptothecin. We 
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were interested in the biosynthesis of 10′ functionalized strictosidine as it provides a 
chemical handle for the rapid derivatization of strictosidine-derived MIAs. 10-
hydroxystrictosidine is synthesized via the condensation of 5-hydroxytryptamine 
(serotonin) and secologanin, rather than tryptamine and secologanin as in the case of 
strictosidine. Modifications at the 5′ position of tryptophan have been shown to be 
processed by MIA enzymes in Catharanthus roseus to produce 10′ modified ajmalicine, 
serpentine, and tabersonine
46
. In this spirit, 10-hydroxystrictosidine may enable the 
biosynthesis of modified MIAs, such as 10-hydroxycamptothecin (14), which has higher 
anticancer activity than camptothecin
18
 (Figure 2.3). Modified MIAs such as 10-
hydroxycamptothecin can serve as better semisynthesis intermediates than camptothecin 
for the chemical synthesis of more water-soluable derivatives
18
, such as the colon 
anticancer drug irinotecan (15) and the ovarian and lung cancer drug topotecan (16). 
More generally, modified MIAs can serve as synthons for the semisynthesis of novel 
complex alkaloids with potential therapeutic activities. 
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Figure 2.3. Modified MIAs for the semisynthesis of pharmaceuticals. Modified 
alkaloids, such as hydroxystrictosidine, have the potential to be biosynthetically 
converted to advanced alkaloids, such as hydroxycamptothecin, via the MIA 
biosynthetic pathway. These alkaloids can be used as functionalized starting 
materials for the semisynthesis of pharmaceuticals. In particular, 
hydroxycamptothecin, which is the 10′ hydroxylated version of camptothecin, could 
enable rapid access to the anticancer drugs topotecan and irinotecan. 
2.3.2 Microbial Synthesis of Tetrahydrobiopterin in S. cerevisiae 
S. cerevisiae does not produce BH4, but guanosine triphosphate (GTP, 17) can be 
rerouted to produce BH4 through the intermediates dihydroneopterin triphosphate (18) 
and pyruvoyl tetrahydropterin (19) using three enzymes: GTP cyclohydrolase I 
(GTPCH), pyruvoyl tetrahydropterin synthase (PTPS), and sepiapterin reductase (SR) 
(Figure 2.4a). Given that BH4 oxidizes to dihydrobiopterin and, subsequently, to 
biopterin in water
47
, we screened for the presence of biopterin in the medium. GTPCH is 
the first committed step in BH4 biosynthesis
48
. S. cerevisiae has an endogenous GTPCH 
as part of the folate biosynthetic pathway and thus requires only expression of 
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heterologous PTPS and SR to produce BH4. Mortierella alpina is the only fungus shown 
to carry the full BH4 biosynthetic pathway from GTP
49
, and, given that S. cerevisiae is 
also a fungus, M. alpina enzymes may be efficiently expressed in this organism. 
Overexpression of M. alpina PTPS and SR in S. cerevisiae produced 0.74 mg/L of BH4, 
measured as biopterin (Figure 2.4b, Figure 2.5). Concerned that this would be an 
insufficient amount of BH4, even for use as a cofactor only, we set out to determine if 
BH4 levels have a limiting effect on alkaloid production. We exogenously fed BH4 to 
yeast cells expressing only a pterin-dependent tyrosine mono-oxygenase to convert 
tyrosine into L-DOPA. No L-DOPA was seen when feeding 0–50 mg/L of BH4, 
suggesting that BH4 oxidizes to dihydrobiopterin or biopterin before reaching the tyrosine 
mono-oxygenase. BH4 must be synthesized intracellularly rather than exogenously fed to 
determine whether 0.74 mg/L BH4 limits alkaloid biosynthesis. 
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Figure 2.4. Microbial synthesis of tetrahydrobiopterin (BH4) in S. cerevisiae. (a) BH4 
biosynthetic pathway from guanosine triphosphate (GTP), which is endogenously 
made by S. cerevisiae. (b) Heat map of biopterin titers (mg/L), as a proxy for BH4 
titers, from the 49 BH4-producing yeast strains. Except for S. cerevisiae 
chromosomal (c), where the chromosomal copy of S. cerevisiae GTPCH was used, 
each enzyme was expressed from a multi-copy plasmid from an inducible galactose 
promoter (PGAL1). Biopterin was quantified using liquid chromatography–mass 
spectrometry (LC/MS). Biopterin titers reported as (-) were not determined. 
Biopterin titers reported as 0.00 were either too low to quantify or undetectable. A 
control strain expressing green fluorescent protein in a three-plasmid system 
showed no biopterin production. The experiments were run in triplicate and shown 
are the means. Standard deviations can be found in Figure 2.5. (c) LC/MS traces 
(extracted ion chromatograms) of BH4 (m/z 242) and oxidation products 
dihydrobiopterin (m/z 240) and biopterin (m/z 238) found intracellularly and in the 
production medium. Standard retention times: BH4 = 2.6 min, dihydrobiopterin = 
5.3 min, biopterin = 4.6 min. Only biopterin was observed in the production 
medium. Full windows of the spectra can be found in Figure 2.5. (d) Pterin-
dependent mono-oxidation of tyrosine to L-DOPA using the original BH4 synthesis 
strain (S. cerevisiae GTPCH, M. alpina PTPS and SR) and the combinatorially 
optimized BH4 synthesis strain (E. coli GTPCH, M. alpina PTPS and SR), both 
strains carrying tyrosine mono-oxygenase. Improving BH4 production improves 
amino acid mono-oxidation. (e) Optimization of BH4 biosynthesis. BH4 synthesis 
pathway: E. coli GTPCH, M. alpina PTPS and SR. For the glucose system, all three 
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enzymes were expressed from a single multi-copy plasmid under control of 
constitutive promoters (PADH1, PTEF1, and PHXT7). (f) BH4 biosynthetic pathway 
bottleneck identification. Biopterin production from galactose in yeast expressing 
each BH4 biosynthetic enzyme from either a single-copy (s) or a multi-copy (m) 
plasmid. All experiments were run in triplicate and shown are the means and 
standard deviations. GTPCH, GTP cyclohydrolase; PTPS, pyruvoyl 




Figure 2.5. Combinatorial production of biopterin. (a) Production levels of biopterin 
were quantified using LC/MS. Production levels reported as 0.00 were either too low 
to quantify or undetectable. Strain PPY810 represents a control strain expressing 
green fluorescent protein in a three-plasmid system. The experiments were run in 
triplicate and shown are the mean and standard deviation. (b) Full window of LC 
traces representing biopterin production in Figure 2.4c. 
So as not to limit alkaloid production due to insufficient BH4, we combinatorially 
overexpressed four GTPCHs, four PTPSs, and three SRs in S. cerevisiae to identify a 
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high-level BH4-producing yeast strain. Among GTPCHs, we screened the enzymes from 





 μM) and has been previously expressed in S. cerevisiae
52
. H. sapiens 
GTPCH has a pI of 5.6
53
, which could aid in its solubility, and it has also been expressed 
in S. cerevisiae
52
. Among PTPSs, we screened the enzymes from M. alpina, Salmo salar, 
the halophile Salinibacter ruber, and the bacteria Phycisphaera mikurensis. S. salar 
PTPS has a specific activity that is 50 times higher, and a KM that is five times lower, 
than that of the canonical human PTPS
54
. We screened the putative PTPS from S. ruber 
because a structural homology model alignment with S. salar PTPS revealed that these 
enzymes have an almost identical active site, except that S. ruber PTPS has a catalytic 
aspartate rather than a cysteine residue
55
 (Figure 2.6). We hypothesized that the 
aspartate’s carboxylate functions as a better acid–base catalyst compared to cysteine’s 
thiol group. We screened the predicted PTPS from P. mikurensis because its active site is 
almost identical to the well-studied Rattus rattus PTPS
56
; however, the P. mikurensis 
PTPS N-terminus has an additional ∼100 amino acids. A bioinformatics search revealed 
that S. cerevisiae lacked any PTPS homologue. Among SRs, we screened the SR from M. 
alpina, a predicted SR from the diatom Thalassiosira pseudonana, which, based on 
structural homology models is hypothesized to be NADH- rather than NADPH-




Figure 2.6. Structural alignment of Salinibacter ruber and Salmo salar pyruvoyl 
tetrahydropterin synthase (PTPS). Structural alignment of homology models of S. 
salar PTPS (cyan) and S. ruber (green) PTPS obtained via structural homology to 
rat PTPS (PDB:1B66) using SWISS-MODEL
81-83
. Presented is a monomer of the 
active site of PTPS (which is composed of three monomers) showing the catalytic 
cysteine residue of S. salar PTPS and corresponding aspartate residue of S. ruber 
PTPS. Biopterin (blue) and Zn(II) (purple) were obtained from the crystal structure 
from rat. Alignment was completed with PyMOL. 
 
Figure 2.7. Structural alignment of Mortierella alpina and Thalassiosira pseudonana 
sepiapterin reductase (SR). Structural alignment of homology models of M. alpina 
SR (green) and T. pseudonana (cyan) SR obtained via structural homology to 
PDB:1Z6Z and 3ICC, respectively, using SWISSMODEL
81-83
. NADPH (yellow) and 
biopterin (dark blue) were obtained from the crystal structure of mouse SR 
(PDB:1SEP). While arginine residues are present in the M. alpina structure to 
stabilize the phosphate group of NADPH, there are no stabilizing residues present in 
the T. pseudonana structure. Alignment was completed with PyMOL. 
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The combination of E. coli GTPCH, M. alpina PTPS, and M. alpina SR resulted in 
the highest biopterin microbial synthesis, at 5.53 mg/L (Figure 2.4b, Figure 2.5). E. coli 
GTPCH outperformed all other GTPCHs, including the endogenous S. cerevisiae 
GTPCH. H. sapiens and M. alpina GTPCH resulted in the lowest biopterin production, 
with 3 of the 12 strains expressing M. alpina GTPCH producing undetectable levels of 
biopterin. PTPS expression showed graded levels of biopterin production with M. alpina 
≈ S. salar > S. ruber > P. mikurensis in most cases. Expression of M. alpina SR resulted 
in statistically significant higher production of biopterin than the S. cerevisiae or T. 
pseudonana SRs in all 32 cases (all P-values < 0.015). No BH4 or dihydrobiopterin were 
found in the medium or inside the cell, and negligible amounts of biopterin were found 
inside the cell, supporting diffusion of biopterin out of the cell (Figure 2.4c). As 
suspected, BH4 levels had a limiting effect on pterin-dependent amino acid 
hydroxylation, judging by the performance of tyrosine mono-oxygenase in different BH4-
producing strains. L-DOPA production from the combinatorially optimized BH4 synthesis 
strain (E. coli GTPCH, M. alpina PTPS and SR) resulted in 5-fold higher L-DOPA levels 
when compared to the initial BH4 synthesis yeast strain (S. cerevisiae GTPCH 
(chromosomal), M. alpina PTPS and SR) (Figure 2.4d). 
2.3.3 Optimization of Tetrahydrobiopterin Biosynthesis 
We hypothesized that increasing the flux through the purine pathway should increase 
GTP levels and, in turn, BH4 production. The parent yeast strain, W303, has a 
nonfunctional phosphoribosylaminoimidazole carboxylase (ade2) gene located upstream 
of GTP in the purine biosynthetic pathway (Figure 2.8). We generated a functional Ade2 
yeast strain and introduced the combinatorially optimized BH4 synthesis pathway, 
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achieving 7.81 mg/L of biopterin, a statistically significant improvement over the 
combinatorially optimized BH4 synthesis pathway in the ade2 strain (5.53 mg/L, P value 
< 0.04) (Figure 2.4e). To identify bottlenecks within the BH4 pathway, we dosed the 
expression of each gene in the combinatorially optimized BH4 synthesis pathway by 
expressing each gene from a single- or multi-copy plasmid using galactose-inducible 
promoters. The highest biopterin production was obtained when GTPCH was expressed 
from a multi-copy plasmid with PTPS and SR expressed from single-copy plasmids, 
producing 9.13 mg/L of biopterin (Figure 2.4f). To help rationalize this result, we 
measured GTPCH, PTPS, and SR mRNA levels when expressed from single- or multi-
copy plasmids (Figure 2.9). GTPCH mRNA levels were lowest when expressed from a 
multi-copy plasmid, while PTPS and SR mRNA levels were lowest when expressed from 
a single-copy plasmid. Thus, the best BH4-producing strain had the lowest mRNA levels 
for each of the three genes, hinting that overexpression of the three enzymes may be a 
burden to the system. Nevertheless, the increase in biopterin production was not 
statistically different from the 7.81 mg/L of biopterin produced when all enzymes were 
expressed from multi-copy plasmids in the Ade2 strain (Figure 2.4f). To produce BH4 
from glucose and to reduce plasmid burden
57,58
, the best enzyme combination was 
expressed in the Ade2 strain from a single multi-copy plasmid using constitutive 
promoters. Surprisingly, the single-plasmid BH4 synthesis pathway resulted in only 7.69 
mg/L of biopterin (Figure 2.4e), not statistically different from the biopterin production 
obtained from the three-plasmid galactose induced system (7.81 mg/L). It is possible that 




Figure 2.8. Purine biosynthetic pathway from the Kyoto Encyclopedia of Genes and 
Genomes (KEGG)
84
. The enzyme encoded by Ade2 is boxed in red. GTP is boxed in 
green. 
 
Figure 2.9. GTPCH, PTPS and SR mRNA levels. Multi-copy: multi-copy plasmid. 
Single-copy: single-copy plasmid. Values represent the mean of two reactions. 
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2.3.4 Tetrahydrobiopterin Recycling for Pterin-dependent Amino Acid Mono-oxidation 
Upon amino acid mono-oxidation, BH4 is converted to BH4-4a-carbinolamine (20). 
Previous work in E. coli has shown the BH4 recycling pathway to be critical to ensure 
continuous supply of the BH4 analogue MH4 in pterin-dependent amino acid mono-
oxidation
31,35
. To provide a continuous supply of BH4 to the amino acid mono-
oxygenases, we established a BH4 recycling pathway in S. cerevisiae. In the recycling 
pathway, BH4-4a-carbinolamine is converted back to BH4 via the intermediate quinoid 
dihydrobiopterin (21) through consecutive reactions by pterin-4a-carbinolamine 
dehydratase (PCD) and dihydropteridine reductase (DHPR) (Figure 2.10a). We measured 
the effect of the H. sapiens BH4 recycling pathway on the pterin-dependent mono-
oxidation of tyrosine to L-DOPA, using the codon optimized Mus musculus tyrosine 
hydroxylase, in (1) the absence of the BH4 biosynthetic and recycling pathways, (2) the 
presence of only the BH4 biosynthetic pathway, and (3) the presence of both the BH4 
biosynthetic and recycling pathways (Figure 2.10b,c, Figure 2.11a). As expected, no L-
DOPA was produced in the absence of the BH4 biosynthetic and recycling pathways. In 
the presence of only the BH4 biosynthetic pathway, L-DOPA was produced at 0.27 mg/L, 
while in the presence of both the BH4 biosynthetic and recycling pathways, L-DOPA was 
produced at 0.33 mg/L. This increase in L-DOPA was not statistically significant, and the 
difference in biopterin levels in the presence or absence of the recycling pathway was not 
statistically significant either (Figure 2.10d). We conclude that high-level BH4 synthesis 
eliminates the necessity of the BH4 recycling pathway at the current rate of tyrosine 
mono-oxidation. To determine if tyrosine was limiting L-DOPA production, we 
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supplemented the media with tyrosine and observed a slight increase in L-DOPA levels 
(Figure 2.12). Thus, improving tyrosine biosynthesis should increase L-DOPA. 
 
 
Figure 2.10. Microbial synthesis of L-DOPA via pterin-dependent tyrosine mono-
oxidation. (a) Schematic representation of the BH4 recycling pathway. (b) 
Representative LC/MS traces for various L-DOPA production strains (extracted ion 
chromatograms for L-DOPA = m/z 198). Traces represent strains expressing (i) only 
tyrosine hydroxylase (TH), (ii) TH and the BH4 synthesis pathway, and (iii) TH, the 
BH4 synthesis pathway, and the BH4 recycling pathway. Trace iv is commercial L-
DOPA standard. Full windows of the spectra can be found in Figure 2.11a. (c) 
Production levels of L-DOPA from galactose in the presence (+) or absence (−) of the 
BH4 synthesis pathway and/or BH4 recycling pathway. (d) Production levels of 
biopterin from galactose in the presence (+) or absence (−) of the BH4 recycling 
pathway. All experiments were run in triplicate and shown are the means and 
standard deviations. Strains carried four multi-copy plasmids in which each gene 
was expressed from galactose inducible promoters (PGAL1 or PGAL10). PCD, pterin-




Figure 2.11. Full windows of LC/MS traces in Figure 2.10b, Figure 2.13b, Figure 
2.13f. L-DOPA, dopamine and serotonin highlighted with a pink (L-DOPA, 
dopamine) or green diamond (serotonin). (a) L-DOPA (13.8 min), (b) dopamine 
(12.8 min), and (c) serotonin (17.2 min). 
 
 
Figure 2.12. Effect of tyrosine on L-DOPA production. In our experiments, 30 mg/L 
of tyrosine is present when producing L-DOPA or dopamine. 
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2.3.5 Microbial Synthesis of Biogenic Amines via Pterin-dependent Mono-oxidation 
Biogenic amines are the immediate precursors to both MIAs and BIAs.(5) To 
microbially synthesize the BIA biogenic amine precursor dopamine from galactose, we 
engineered a yeast strain carrying the BH4 biosynthetic and recycling pathways, tyrosine 
mono-oxygenase, and the codon optimized Sus scrofa aromatic L-amino-acid 
decarboxylase (DDC) (Figure 2.13a). This strain produced dopamine at 1.52 mg/L, while 
no dopamine was produced in the absence of the BH4 biosynthetic and recycling 
pathways (Figure 2.13b,c, Figure 2.11b). To microbially synthesize the MIA biogenic 
amine serotonin from galactose, we engineered a yeast strain carrying the BH4 
biosynthetic and recycling pathways, a truncated codon optimized H. sapiens tryptophan 
hydroxylase
59
, and DDC (Figure 2.13e). This strain produced serotonin at 5.72 mg/L, 
while no serotonin was produced in the absence of the BH4 synthesis and recycling 
pathways (Figure 2.13f,g, Figure 2.11c). In the presence of the amino acid mono-
oxygenase, DDC, and the BH4 biosynthetic pathway, but in the absence of the BH4 
recycling pathway, dopamine was produced at 1.73 mg/L, while serotonin was produced 
at 5.18 mg/L (Figure 2.13c,g). As with the production of L-DOPA, the BH4 recycling 
pathway had no statistically significant effect on biogenic amine production. The 
dopamine- and serotonin-producing strains had similar levels of biopterin with and 
without the BH4 recycling pathway (Figure 2.13d,h). To determine if tryptophan was 
limiting serotonin production, we supplemented the media with tryptophan. Indeed, 
increasing extracellular tryptophan levels increased serotonin production (Figure 2.14). 
Thus, improving yeast tryptophan biosynthesis should increase serotonin levels. 
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Figure 2.13. Microbial synthesis of biogenic amines via pterin-dependent mono-
oxidation. (a) Schematic representation of dopamine biosynthesis. (b) 
Representative LC/MS traces for various production strains (extracted ion 
chromatograms (EIC) for dopamine = m/z 154). Traces represent strains expressing 
(i) tyrosine hydroxylase (TH), aromatic-l-amino-acid decarboxylase (DDC), the 
BH4 synthesis pathway, and the BH4 recycling pathway, (ii) TH and DDC, and (iii) 
TH, DDC, and the BH4 synthesis pathway. Trace iv is commercial dopamine 
standard. Full windows of the spectra can be found in Figure 2.11b. (c) Production 
levels of dopamine in the presence (+) or absence (−) of the BH4 synthesis pathway, 
and/or the BH4 recycling pathway. (d) Production levels of biopterin in the presence 
(+) or absence (−) of the BH4 recycling pathway. (e) Schematic representation of 
serotonin biosynthesis. (f) Representative LC traces for various production strains 
(EIC for serotonin = m/z 177). Traces represent strains expressing (i) tryptophan 
hydroxylase (TPH), DDC, the BH4 synthesis pathway, and the BH4 recycling 
pathway, (ii) TPH and DDC, and (iii) TPH, DDC, and the BH4 synthesis pathway. 
Trace iv is commercial serotonin standard. Full windows of the spectra can be found 
in Figure 2.11c. (g) Production levels of serotonin in the presence (+) or absence (−) 
of the BH4synthesis pathway and/or BH4 recycling pathway. (h) Production levels of 
biopterin in the presence (+) or absence (−) of the BH4 recycling pathway. All 
experiments were run in triplicate and shown are the means and standard 
deviations. Strains carried four multi-copy plasmids in which each gene was 
expressed from galactose inducible promoters (PGAL1 or PGAL10). 
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Figure 2.14. Effect of tryptophan on serotonin production. In our experiments, 
tryptophan is not supplemented when producing serotonin or hydroxystrictosidine. 
2.3.6 Microbial Synthesis of the Modified MIA 10-Hydroxystrictosidine 
Although several microbial strains have been engineered for the production of 
BIAs
19-25
, engineering of MIA microbial platforms has lagged behind
60
. Further, to our 
knowledge no modified alkaloid has been produced microbially to date. Microbial 
synthesis of modified alkaloids has the potential to generate more amenable intermediates 
for chemical derivatization to obtain final therapeutics. Therefore, we focused our pterin-
dependent biogenic amine-producing strain toward the production of the modified MIA 
hydroxystrictosidine. To microbially synthesize hydroxystrictosidine from galactose and 
secologanin, we used the serotonin-producing strain, carrying the BH4 recycling pathway 
and expressing the Ophiorrhiza pumila strictosidine synthase
61
 with the vacuolar tag 
removed so as to avoid enzyme secretion
62
 (Figure 2.15a). The strain produced both R- 
and S-hydroxystrictosidine isomers. (Figure 2.15b, Figure 2.16). Given that 
hydroxystrictosidine is not commercially available, we characterized the compounds 
using tandem mass spectrometry and high resolution mass spectrometry (Figure 2.15c,d, 
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Figure 2.17). To improve upon the inducible four-plasmid system, which has drawbacks 
in terms of carbon source, plasmid burden, stability, and the reuse of promoters, we 
engineered a three-plasmid system using multi-copy plasmids with the enzymes under 
control of constitutive promoters. The four- and three-plasmid systems produced similar 
levels of hydroxystrictosidine (Figure 2.15e,Table 2-1). Interested in whether the BH4 
recycling pathway had an effect on hydroxystrictosidine levels, we removed the recycling 
pathway in both the four- and three-plasmid systems and saw that the BH4 recycling 
pathway had no significant impact on hydroxystrictosidine production. Given this 
observation, we engineered a two-plasmid system without the BH4 recycling pathway; 
however, this system also failed to improve hydroxystrictosidine production. 
Interestingly, all the hydroxystrictosidine-producing yeast strains resulted in a mixture of 
R- and S-hydroxystrictosidine isomers even though previous in vitro work feeding 
tryptamine and secologanin to strictosidine synthase at pH = 7 resulted in the 
stereoselective synthesis of S-strictosidine
61
. Removing strictosidine synthase from the 
hydroxystrictosidine-producing strain resulted in similar R- and S-hydroxystrictosidine 
levels (Figure 2.18). This indicated that, at the low pH of the yeast medium (pH = 5–3), 
secologanin and serotonin were coupling chemically rather than enzymatically to produce 
a mixture of hydroxystrictosidine isomers
63
. Indeed, strictosidine synthase retains less 
than one tenth of its activity at pH = 4–3
64
 and has 3 orders of magnitude less catalytic 





Figure 2.15. Microbial synthesis of the modified MIA 10-hydroxystrictosidine. (a) 
Schematic of hydroxystrictosidine biosynthesis. (b) Representative LC/MS trace 
(multiple reaction monitoring hydroxystrictosidine 547.60 → 530.00 transition) for 
the yeast strain (PPY650) carrying tryptophan hydroxylase, aromatic-L-amino-acid 
decarboxylase, strictosidine synthase, and the BH4 biosynthesis and recycling 
pathways in the presence or absence of 0.4 mM secologanin. S = (S)-
hydroxystrictosidine; R = (R)-hydroxystrictosidine. Full window of the spectra can 
be found in Figure 2.16. (c) Tandem mass spectrum of microbially synthesized S-
hydroxystrictosidine. (d) High-resolution mass spectrum of microbially produced S-
hydroxystrictosidine. (e) (S) and (R)-hydroxystrictosidine production in S. 
cerevisiae. DDC, aromatic-l-amino-acid decarboxylase; TPH, tryptophan 




Table 2-1. Overview of alkaloid and precursor production. 
 
Arrows represent presence of the enzyme.  nd = not detectable.  Amount produced is 
represented by the mean ± standard deviation for samples run in triplicate.  GTPCH: GTP 
cyclohydrolase; PTPS: pyruvoyl tetrahydropterin synthase; SR: sepiapterin reductase; 
PCD: pterin-4a-carbinolamine dehydratase; DHPR: dihydropteridine reductase; TPH: 
tryptophan hydroxylase; TH: tyrosine hydroxylase; DDC: aromatic-L-amino-acid 
decarboxylase; STR: strictosidine synthase. 
 
 
Figure 2.16. Full window of multiple reaction monitoring for Figure 2.15b. Shown 
hydroxystrictosidine transition: 547.60 → 530.00 transition. 
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Figure 2.17. Mass spectral characterization of hydroxystrictosidine isomers. (a) LC 
trace (extracted ion chromatogram corresponding to hydroxystrictosidine, m/z 547, 
extracted from full scan data) from high resolution mass spectrometry analysis. (b) 
High-resolution mass spectrum of microbially-produced S-hydroxystrictosidine and 
R-hydroxystrictosidine. (c) Theoretical high-resolution mass spectrum of 
hydroxystrictosidine. (d) LC trace for product ions of m/z 547 from tandem mass 
spectrometry analysis. (e) Tandem mass spectra of microbially-produced S-
hydroxystrictosidine and R-hydroxystrictosidine. 
 
Figure 2.18. Isomer ratios produced in the presence (STR +, PPY650) or absence 
(STR -, PPY649) of strictosidine synthase using yeast synthetic media (pH=5-3). 
Green: S-hydroxystrictosidine; Yellow: R-hydroxystrictosidine. 
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2.3.7 Determining Strictosidine Synthase Functionality 
To determine if strictosidine synthase was functionally expressed in the 
hydroxystrictosidine-producing yeast strain, we examined the level of spontaneous and 
enzymatic hydroxystrictosidine synthesis under different conditions. First, we confirmed 
that spontaneous condensation of serotonin and secologanin does not occur at pH = 7, but 
does at pH = 3, producing both hydroxystrictosidine isomers (Figure 2.19a, Figure 
2.20a), explaining why in vitro strictosidine synthase studies at pH = 7 do not exhibit 
spontaneous condensation and produce only the S-isomer. Next, we tested 
hydroxystrictosidine formation using the lysate of yeast cells expressing strictosidine 
synthase. When the lysate was placed at pH = 3 and fed serotonin and secologanin, both 
hydroxystrictosidine isomers were formed, while the same experiment at pH = 7 resulted 
in only the S-isomer (Figure 2.19b, Figure 2.20b), demonstrating that strictosidine 
synthase is functionally expressed in yeast. Isomer identification was determined due to 
the fact that strictosidine synthase is known to form only the S-isomer
61
 while the 
spontaneous chemical condensation produces both R- and S-isomers, with the R-isomer 
being the major product
63
. Next, we used intact yeast cells expressing strictosidine 
synthase, fed serotonin and secologanin, and cultured the cells for 136 h using standard 
(pH = 4–2.5, Figure 2.21) or buffered (pH = 7–5, Figure 2.21) synthetic complete media. 
Yeast cells in the buffered media resulted in the synthesis of only S-hydroxystrictosidine 
(Figure 2.19c, Figure 2.20c). Finally, we showed that strictosidine synthase is necessary 
for S-hydroxystrictosidine production in yeast and that the reaction was not catalyzed by 
an endogenous yeast enzyme (Figure 2.19d, Figure 2.20d, Figure 2.22). These results 
demonstrate that strictosidine synthase is functionally expressed in the 
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hydroxystrictosidine-producing yeast strain, that the enzymatic reaction leading to the S-
isomer is taking place intracellularly, and that secologanin is crossing the yeast cell 
membrane. In standard yeast synthetic complete media, however, the spontaneous 





Figure 2.19. Analysis of the 10-hydroxystrictosidine isomer ratio. All reactions 
contain 0.4 mM each of secologanin and serotonin. LC traces (extracted ion 
chromatograms for hydroxystrictosidine = m/z 547) for (a) the chemical reaction in 
phosphate buffer at pH = 3 (black) or pH = 7 (red); (b) the reaction in cell lysate of 
yeast expressing strictosidine synthase (PPY827) adjusted to pH = 3 (black) or pH = 
7 (red); (c) in vivo reaction using intact yeast cells expressing strictosidine synthase 
(PPY827) in standard yeast media (black) or pH = 7 buffered media (red); and 
(d) in vivo reaction using intact yeast cells expressing either strictosidine synthase 
(PPY827, solid red line) or yeast expressing a blank plasmid (PPY828, dotted red 
line) in pH = 7 buffered media. Full windows of the spectra can be found in Figure 





Figure 2.20. Full windows of LC/MS traces in Figure 2.19 (extracted ion 
chromatograms for hydroxystrictosidine, m/z 547). S-hydroxystrictosidine, rt=6.1 
min. R-hydroxystrictosidine, rt=6.8 min. Isomer identification was determined due 
to the fact that strictosidine synthase is known to form only the S-isomer. A single 




Figure 2.21. pH of media over time. (a) pH of wild-type W303 yeast grown in 
synthetic complete media (black) or buffered synthetic complete media (25mM 
K2HPO4, red). (b) Cell growth monitored by absorption at OD600. 
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Figure 2.22. Full window for multiple reaction monitoring (MRM) analysis for 
Figure 2.19d. Only one peak can be found in the MRM spectrum corresponding to 
the characteristic hydroxystrictosidine transition 547.60 → 530.00. All other peaks 
in the Figure 2.19d (and Figure 2.20d) LC/MS trace have m/z value of 547, but do 
not have the characteristic hydroxystrictosidine transition 547.60→530. 
2.4 Discussion 
Together, these results establish the first microbial synthesis of a modified alkaloid, 
specifically a modified MIA, representing an alkaloid family with important medicinal 
compounds, including anticancer, antimalarial, and antiarrhythmic agents. We produced 
hydroxystrictosidine from glucose and secologanin in S. cerevisiae by leveraging the 
pterin-dependent mono-oxidation of tryptophan using microbially produced BH4 as a 
cofactor. Pterin-dependent mono-oxidation of tryptophan was necessary as no known 
natural enzyme oxidizes tryptophan akin to how tyrosinase oxidizes tyrosine, and plant 
enzymes used to convert tryptophan to serotonin can be promiscuous. We chose S. 
cerevisiae as the microbial host due to its robustness to industrial conditions, which 
makes this MIA-producing platform attractive for continued use. Further, the presence of 
compartments in S. cerevisiae with unique pH values and metal concentrations can be 
exploited to express downstream MIA pathway enzymes at the ideal conditions for 
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maximal enzymatic activity or to prevent byproduct formation. Finally, although in this 
work we fed secologanin to the microbe, in the future, secologanin can also be 
biosynthesized from glucose as the nine-step secologanin biosynthetic pathway from 
geranyldiphosphate is known and has been reconstituted in yeast
60,66
. 
We were surprised by the non-necessity of the BH4 recycling pathway for amino acid 
mono-oxidation and ultimately hydroxystrictosidine production, even though a BH4 





 in E. coli when using the cofactor analogue MH4. In our engineered 
yeast strain, BH4 synthesis alone is sufficient to drive robust amino acid mono-oxidation, 
and aromatic amino acid levels are currently limiting alkaloid production. Using the 
pterin-dependent mono-oxidation strategy, L-DOPA is produced to 0.33 mg/L, which is 
comparable to L-DOPA production in yeast using a tyrosinase at ∼0.1 mg/L29. 
Interestingly, L-DOPA production was higher (∼1 mg/L) in the BH4-producing strain 
synthesizing slightly less BH4 (5.53 mg/L vs 7.81 mg/L) due to a nonfunctional mutation 
in the ade2 gene. The resource allocation for the increased BH4 production may be 
detrimental to the production of tyrosine, and, thus limiting for L-DOPA. Therefore, 
matching the levels of the BH4 cofactor supply to the demand of the amino acid mono-
oxygenase should enable further improvement in the yield of amino acid mono-oxidation 
and, in turn, in BIA or MIA production. Increasing the tyrosine supply and dynamically 
regulating the BH4 levels to match the demand of the amino acid mono-oxygenase may 
enable the production of L-DOPA at the levels achieved in E. coli, 293 mg/L
21
. 
Using standard yeast media, both R- and S-hydroxystrictosidine isomers are 
produced; through testing various reaction conditions, we conclude that strictosidine 
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synthase is functional in our strain, although at the low pH of the yeast media the 
chemical condensation of serotonin and secologanin prevails. While the enzymes in the 
MIA pathway are likely to prefer one isomer over the other for further processing, 
synthesis of both hydroxystrictosidine isomers may not be detrimental to the production 
of more complex MIAs as later enzymes in MIA pathways, such as strictosidine 
glucosidase, are able to turn over the R-isomer, albeit at lower rates when compared to 
the S-isomer
67,68
. Further, enzymes capable of turning over alkaloid isomer mixtures have 
also been seen in other alkaloid families, such as BIAs
19
. Alternatively, later enzymes in 
the MIA pathway may be able to convert only one isomer, as in the case of the berberine 
bridge enzyme in the BIA pathway
69
, thus reducing the concerns of producing a mixture 
of hydroxystrictosine isomers early on in the pathway. 
There are several opportunities and some key challenges to improving the yield of 
amino acid mono-oxidation and, in turn, MIA production. First, we show that tyrosine 
and tryptophan levels limit the system; thus, increasing aromatic amino acid supply via 
introduction of feedback-resistant enzyme mutants in aromatic amino acid metabolism, 
such as Aro4
70
, or utilizing a tyrosine overproducing strain
71
, should enable 
straightforward increases in amino acid mono-oxidation. Second, our system does not 
currently take advantage of the power of the BH4 recycling system, as biogenic amine 
levels are similar in the presence and absence of the recycling system. Screening or 
engineering aromatic amino acid mono-oxidases with increased in vivo activity should 
also increase aromatic amino acid mono-oxidation. Finally, the BH4 synthesis and 
recycling pathways could be integrated to reduce plasmid burden, and the MIA pathway 
enzymes could be colocalized to increase flux through the pathway
72
. The major 
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challenge with any of these potential approaches to improving the yield of aromatic 
amino acid mono-oxidation is the low-throughput of the chromatography-based screens 
required to detect and quantify these compounds, which take close to one hour per 
sample. Biosensors for key compounds in the pathway, such as hydroxylated amino 
acids
29
, biogenic amines, or, ideally, the terminal MIAs, should enable the faster 
optimization of this and other metabolic pathways with products that are neither 
colorimetric nor fluorescent. A general obstacle is that a new biosensor must be 
engineered for every chemical of interest, and current strategies to rapidly engineer user-
specified chemical biosensors are at the proof-of-principal stage
73
 or still on the drawing 
board. 
The strains reported in this work could be further optimized for production of (1) 
BH4, itself being a treatment for phenylketonuria
74
, (2) hydroxytryptophan, serotonin, and 
serotonin derivatives, key compounds in depression treatment and studies
75-77
, (3) DOPA 
and dopamine, important compounds related to Parkinson’s disease
78
, and (4) advanced 
alkaloids, including anticancer agents. The BH4-producing yeast strain could be used for 
the synthesis of both MIAs and BIAs, by introducing different amino acid mono-
oxygenases. For example, the dopamine-producing strain can be rapidly adapted to 
produce BIAs by using norcoclaurine synthase and hydroxyphenylacetaldehyde to 
produce norcoclaurine (22). Ultimately, we envision the MIA-producing strain being 
used in the biosynthesis of modified and non-natural MIAs or as a plant pathway 
discovery tool to identify unknown steps in MIA biosynthetic pathways. For instance, we 
can use the hydroxystrictosidine platform to screen cDNA libraries of plant tissues 
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known to overproduce MIAs to rapidly identify missing steps in MIA biosynthetic 
pathways to medically important alkaloids. 
2.5 Materials and Methods 
2.5.1 Reagents 
Tetrahydrobiopterin, dihydrobiopterin, and biopterin were purchased from Cayman 
Chemical (81880, 81882, and 10007662). Dopamine and vanillin were purchased from 
Alfa Aesar (A11136 and A11169). L-DOPA and serotonin were purchased from TCI 
America (D0600 and S0370). Secologanin and tryptophan were purchased from Sigma-
Aldrich (50741-5MG-F and T0254). 5-Chlorotryptamine was purchased from Ark 
Pharm, Inc. (AK-32281). 
2.5.2 Construction of W303-Ade2+ Strain 
S. cerevisiae W303 were transformed with AME245 and AME246 via an adapted 
electroporation protocol. Transformed cells were plated and subsequently patched on 
synthetic complete media with 2% glucose lacking adenine (SD (Ade-)). To confirm the 
presence of a functional Ade2, genomic DNA from multiple patches was isolated, the 
mutation was amplified by PCR using primers AME128/AME247, and the PCR product 
sequenced with AME247. 
2.5.3 Plasmid Construction 
To construct pAME18, 20, 22-26, and 28, genes were amplified from plasmids 
carrying codon-optimized nucleotide sequences of M. alpina GTPCH, H. sapiens 
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GTPCH, M. alpina PTPS, S. salar PTPS, S. ruber PTPS, P. mikurensis PTPS, M. alpina 
SR, and T. pseudonana SR with primers AME143/AME144, AME141/AME139, 
AME149/AME150, AME147/AME148, AME151/AME152, AME153/AME154, 
AME165/AME166, or AME165/AME167, respectively, and cloned into pESC-Leu2 at 
BamHI/HindIII (pAME18, 20), pESC-Trp1 at BamHI/SacII (pAME22-25), or pESC-
His3 at BamHI/SacII (pAME26, 28). To construct pAME17, E. coli GTPCH was 
amplified from the E. coli DH10B genome with primers AME163/164. The gene product 
was re-amplified with primers AME135/140 and cloned into pESC-Leu2 at 
BamHI/HindIII. To construct pAME19, S. cerevisiae GTPCH was amplified from S. 
cerevisiae W303 genome with primers AME161/162, and re-amplified with primers 
AME137/142. The gene product was cloned into pESC-Leu2 at BamHI/HindIII. To 
construct pAME27, S. cerevisiae SR was amplified from S. cerevisiae W303 genome 
with primers AME168/169, and re-amplified with primers AME180/183. The gene 
product was cloned into pESC-His3 at BamHI/SacII. To construct pAME3, 29-30, green 
fluorescent protein (GFP) was amplified from pEGFP with primers AME123/124 and 
cloned into pESC-Leu2, pESC-Trp1, or pESC-His3, respectively, at BamHI/HindIII 
(Leu2) or BamHI/SacII (Trp1, His3). Constructs were sequence verified using primers 
AME104 and AME105. 
To construct pAME53-55, the region between terminators TADH1 and TCYC1 was 
amplified from pAME26, 22, or 17 using primers AME184/AME185 and cloned into 
pRS413, pRS414, or pRS415, respectively, at BamHI/HindIII. Constructs were sequence 
verified using primers MH100 and MH101. 
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To construct pAME22PCD and pAME26DHPR, PCD and DHPR genes were 
amplified from plasmids carrying the codon optimized genes with primers SS152/SS153 
or AME241/AME242, respectively, and cloned into pAME22 or pAME26, respectively, 
at NotI/SacI. Constructs were sequence verified using primers AME229 and AME104. 
To construct pSS61, the STR gene was amplified from pSS42 with primers 
SS159/SS160 and cloned into pESC-Ura3 at BamHI/HindIII. To construct pSS66, the 
DDC gene was amplified from pSS62 with primers SS157/SS158 and cloned into 
pAME17 at NotI/SacI. To construct pSS68, the TH gene was amplified from pSS64 with 
primers SS179/SS180 and cloned into pESC-Ura3 at NotI/SacI. To construct pSS70, the 
TPH gene was amplified from pSS44 with primers SS207/SS208 and cloned into pESC-
Ura3 at BamHI/HindIII. To construct pSS71, the TPH gene was amplified from pSS44 
with primers SS177/SS178 and cloned into pSS61 at NotI/SacI. Constructs were 
sequence verified using primer SS112. To construct pAME63, the DDC gene was 
amplified from pSS62 with primers SS157/SS158 and cloned into pESC-Leu2 at 
NotI/SacI. To construct pAME64, the STR gene was amplified from pSS42 with primers 
SS159/AME406 and cloned into pESC-Ura3 at BamHI/HindIII. Constructs were 
sequence verified using primers AME229/AME230 (pAME63) or AME104/AME105 
(pAME64). 
To construct pAME56-58, assembly similar to sewing PCR was utilized. Fragments 









D,pSS67. After amplification, PCR products were gel purified. To create pAME56-58, 
fragments were sewn together using primers AME384/AME389 (PTEF1_PHXT7, THXT7, 
PADH1g, DDC, TPH, STR), AME363/AME374 (PTEF1_PHXT7, THXT7, PADH1g, GTPCH, 
PTPS, SR), and AME375/AME383 (PTEF1_PHXT7, THXT7, PADH1ng, PCD, DHPR), 
respectively, using a typical PCR protocol and equimolar amounts of fragments. 
Resulting products were gel purified and combined with respective vector fragments 
(from pAME22PCD, pAME26DHPR, pSS67, respectively) via Gibson assembly
79
. 
Sequencing was obtained using primers 
AME105/AME229/AME396/AME397/AME369/AME370/AME372. 
2.5.4 Yeast Transformation 
A modified electroporation method
80
 was utilized to transform S. cerevisiae W303 or 
W303-Ade2
+
. Modifications included no DNA precipitation step and immediately after 
electroporation, cells were rescued with YPD and left at room temperature overnight 
before plating on selection media plates. 
2.5.5 Microbial Synthesis of Tetrahydrobiopterin 
Overnight cultures of strains PPY750, 752–793, and 797–810 in synthetic complete 
media with 2% glucose lacking histidine, tryptophan, and leucine (SD (HWL–)) were 
used to inoculate 5 mL of synthetic complete media with 2% galactose lacking histidine, 
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tryptophan, and leucine (SCgal (HWL–)) to OD600 = 0.1 and incubated for 136 h at 30°C 
(250 rpm). Overnight culture of strain PPY749 in synthetic complete media with 2% 
glucose lacking histidine (SD (H–)) was used to inoculate 5 mL of synthetic complete 
media with 2% galactose lacking histidine (SCgal (H–)) to OD600 = 0.1 and incubated for 
136 h at 30°C (250 rpm). Overnight culture of strain PPY751 in synthetic complete 
media with 2% glucose lacking histidine and tryptophan (SD (HW–)) was used to 
inoculate 5 mL of synthetic complete media with 2% galactose lacking histidine and 
tryptophan (SCgal (HW–)) to OD600 = 0.1 and incubated for 136 h at 30°C (250 rpm). 
After incubation, cultures were centrifuged for 5 min at 3230 x g, the supernatant was 
filtered, vanillin was added as an internal standard and samples were 
analyzed via LC/MS. For quantification of biopterin in L-DOPA, dopamine, and 
serotonin-producing strains, 5-chlorotryptamine was used as an internal standard. 
2.5.6 Microbial Synthesis of L-DOPA, Dopamine, Serotonin, and Hydroxystrictosidine 
Overnight cultures of strains PPY646, 649–650, 658, 679, 741, 743, 946−948, and 
955 in synthetic complete media with 2% glucose lacking histidine, tryptophan, leucine, 
and uracil (SD (HWLU–)) were used to inoculate 5 mL of synthetic complete media with 
2% galactose lacking histidine, tryptophan, leucine, and uracil (SCgal (HWLU–)) to 
OD600 = 0.1. Overnight cultures of strains PPY744 and 748 in SD (HWU
–) were used to 
inoculate 5 mL of fresh SD (HWU–) to OD600= 0.1. Overnight culture of strain PPY740 in 
SD (HW–) was used to inoculate 5 mL of fresh SD (HW–) to OD600 = 0.1. For 
hydroxystrictosidine production (strains PPY649, 650, 740, 744, 748, and 955), 
secologanin (solution in water) was added at the time of inoculation to a final 
concentration of 0.4 mM (150 mg/L). After inoculation, all strains were incubated for 136 
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h at 30°C (250 rpm). The cultures were then centrifuged for 5 min at 3230 x g, the 
supernatant was filtered, 5-chlorotryptamine (L-DOPA, dopamine, serotonin) or vanillin 
(hydroxystrictosidine) was added as an internal standard, and the samples were 
analyzed via LC/MS. 
2.5.7 Biopterin Quantification 
LC/MS analysis was completed using an Agilent 1100/1260 series system equipped 
with a 1260 ALS autosampler and a 6120 Single Quadrupole LC/MS with a Poroshell 
120 SB-Aq 3.0 mm × 100 mm × 2.7 μm column and an electrospray ion source. LC 
conditions: solvent A—150 mM acetic acid with 0.1% formic acid; solvent B—methanol 
with 0.1% formic acid. Gradient: 4 min ramp from 95%:5%:0.2 (A:B:flow rate in 
mL/min) to 70%:30%:0.2, 6 min ramp to 40%:60%:0.2, 2 min ramp to 2%:98%:0.2, 2 
min ramp to 2%:98%:0.5, 4 min at 2%:98%:0.5, 1 min ramp to 95%:5%:0.5, 7 min at 
95%:5%:0.5, and 1.5 min post time. MS acquisition (positive ion mode) included 25% 
scan from m/z 100–600, 25% scan from m/z 230–260, 25% scan from m/z 145–165, and 
25% selected ion monitoring (SIM) for BH4 (m/z 242.1), dihydrobiopterin (m/z 240.1), 
biopterin (m/z 238.1), and vanillin (m/z 153.1). Quantitation was performed by obtaining 
the area under the peak in the extracted ion chromatogram (EIC) for the desired m/z value 
from the SIM signal. For biopterin quantification in L-DOPA-, dopamine-, and serotonin-
producing strains, 5-chlorotryptamine (m/z 195.1) was used as an internal standard 
instead of vanillin. Area was converted to concentration using standard curves produced 
from commercially available biopterin. Retention times were determined using 
commercially available standards. 
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2.5.8 Quantification of L-DOPA, Dopamine, and Serotonin 
LC/MS system and solvent composition was the same as the one used in the analysis 
of biopterin. LC gradient: 8 min ramp from 95%:5%:0.05 to 70%:30%:0.05, 6 min ramp 
to 40%:60%:0.05, 1 min ramp to 40%:60%:0.1, 9 min ramp to 2%:98%:0.1, 1 min at 
2%:98%:0.1, 5 min ramp to 2%:98%:0.3, 0.1 min ramp to 2%:98%:0.5, 3.9 min at 
2%:98%:0.5, 1 min ramp to 95%:5%:0.5, 7 min at 95%:5%:0.5, and 3.5 min post time. 
MS acquisition (positive ion mode) included 33% scan from m/z 100–600, 33% scan 
from m/z 120–240, and 33% SIM for L-DOPA (m/z 198.2), dopamine (m/z 154.2), 
hydroxytryptophan (m/z 221.2), serotonin (m/z 177.2), and 5-chlorotryptamine 
(m/z 195.1). Quantitation was performed by obtaining the area under the peak in the EIC 
for the desired m/z value from the SIM signal. Area was converted to concentration using 
standard curves produced from commercially available L-DOPA, dopamine and serotonin 
dissolved in media taken from a culture of strain PPY810 grown under the same 
conditions as production samples. Traces used for the L-DOPA standard curve were 
background subtracted using just media. Retention times were determined using 
commercially available standards. 
2.5.9 Mass Spectral Analysis of Hydroxystrictosidine 
High resolution mass spectrometry (HRMS) and tandem mass spectrometry (MS–
MS) analysis of hydroxystrictosidine was performed at the Mass Spectrometry Facility at 
Georgia Tech. MS–MS was done using a Waters Quattro LC mass spectrometer with a 
Gemini 2 mm × 150 mm × 5 μm C18 column from Phenomenex. LC conditions: solvent 
A—95%:5% water:acetonitrile; solvent B—5%:95% water:acetonitrile. Gradient: 7 min 
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at 100%:0% (A:B), 37 min ramp to 0%:100%, 8 min at 0%:100%, 1 min ramp to 
100%:0%, and 7 min at 100%:0%. Flow rate was 0.2 mL/min. HRMS was done using a 
Thermo LTQ Orbitrap XL equipped with a Nano ACQUITY UPLC with a BEH130 300 
μm × 100 mm × 1.7 μm C8 column from Waters. Solvent A—10 mM ammonium acetate 
in water; solvent B—acetonitrile. Gradient: 5 min at 95%:5% (A:B), 40 min ramp to 
70%:30%, 5 min at 70%:30%, 2 min ramp to 5%:95%, 3 min at 5%:95%, 1 min ramp to 
95%:5%, and 4 min at 95%:5%. Flow rate was 8 μL/min. Multiple Reaction Monitoring 
(MRM) was done on the Waters Quattro LC mass spectrometer using the same column 
and LC gradient using solvent A—95%:5%:0.1% water:acetonitrile:formic acid; solvent 
B—5%:95%:0.1% water:acetonitrile:formic acid. MRM parameters: 
hydroxystrictosidine: transition 547.60 → 530.00, cone voltage 20 V, collision energy 35 
eV; transition 547.60 → 298.00, cone voltage 20 V, collision energy 35 eV. Vanillin: 
transition 152.80 → 92.80, cone voltage 25 V, collision energy 15 eV; transition 152.80 
→ 124.80, cone voltage 25 V, collision energy 15 eV. Camptothecin: transition 349.10 
→ 305.00, cone voltage 45 V, collision energy 35 eV; transition 349.10 → 220.00, cone 
voltage 45 V, collision energy 40 eV. Reported hydroxystrictosidine counts were 
obtained using 547.60 → 530.00 transition. Vanillin internal standard transition used 
152.80 → 92.80. 
2.5.10 Hydroxystrictosidine Isomer Ratios 
For the chemical reactions, secologanin and serotonin were mixed to a final 
concentration of 0.4 mM each in pH = 3 or pH = 7 phosphate buffer (135 mM NaCl, 2.7 
mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4). Solutions were mixed and incubated for 
136 h at 30°C (250 rpm). After incubation, solutions were analyzed using LC/MS. For 
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lysate experiments, an overnight culture of PPY827 in synthetic complete media with 2% 
glucose lacking uracil (SD(U−)) was used to inoculate 5 mL of synthetic complete media 
with 2% galactose lacking uracil SCgal (U–) to OD600 = 0.1. The culture was incubated for 
24 h at 30 °C (250 rpm). After incubation, the culture was centrifuged at 3230 x g for 5 
min, the supernatant was removed, and the pellet was resuspended in 1.5 mL phosphate 
buffer. The pellet was lysed by sonication using a Misonix Sonicator 3000 at 5.0 output 
level for 20 s, 20 s rest, for a total six pulses. The lysate was centrifuged, and supernatant 
was collected. The pH of the lysate was adjusted to either pH = 3 or pH = 7, and 
secologanin and serotonin were added to a final concentration of 0.4 mM each. After 
mixing, the lysates were incubated for 136 h at 30°C (250 rpm), after which the lysates 
were analyzed using LC/MS. For in vivo intact cell experiments, overnight cultures of 
strains PPY827 and PPY828 in SD (U–) were used to inoculate 5 mL of SCgal (U–) or 
SCgal (U–) buffered with 25 mM K2HPO4 (pH = 7) to OD600 = 0.1. Secologanin and 
serotonin were added to a final concentration of 0.4 mM each and the cultures were 
incubated for 136 h at 30 °C (250 rpm). After incubation, all cultures were centrifuged 
for 5 min at 3230 x g, and the supernantant was filtered and analyzed via LC/MS. The 
column compartment was kept constant at 28°C. LC/MS analysis was completed on the 
Agilent system described above. Gradient: 0.25 min ramp from 95%:5% (A:B) to 
70%:30%, 4.75 min ramp to 68%:32%, 2 min ramp to 30%:70%, 1 min at 30%:70%, 
0.50 min ramp to 95%:5%, and 5.5 min at 95%:5%. Flow rate was 0.4 mL/min. MS 
acquisition (positive ion mode) included 30% scan from m/z 100–600 and 70% SIM for 
ions related to alkaloid formation (dopamine, m/z 154; tryptamine, m/z 161; 
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serotonin, m/z 177; tyrosine, m/z 182; L-DOPA, m/z 198; tryptophan, m/z 205; 5-
hydroxytryptophan, m/z 221; strictosidine, m/z 531; hydroxystrictosidine, m/z 547). 
2.5.11 Statistical Analysis 
Two-tailed, paired T-tests were performed in Microsoft Excel. 
2.5.12 Yeast Cell Lysis for Intracellular Biopterin Determination 
After 136 h of microbial production, cultures were centrifuged at 3230 x g for 5 min. 
The supernatant was removed and filtered with a 0.2 µm filter. The pellet was frozen at -
80°C, thawed, washed with 1 mL water, and resuspended in 250 µL water. 250 µL 0.2M 
NaOH was mixed in and the cells remained at room temperature for 10 minutes. The 
lysate was centrifuged and filtered. Both supernatant and lysate were analyzed using 
liquid chromatography/ mass spectrometry (LC/MS). 
2.5.13 Determination of SR Open Reading Frame from T. pseudonana 
As only a portion of the amino acid sequence is known for the predicted SR from T. 
pseudonana, we searched upstream and downstream of the sequence in the genome to 
obtain a complete open reading frame. 
2.5.14 Determiniation of GTPCH, PTPS, and SR mRNA Levels 
Overnight cultures of strain PPY949-950 in synthetic complete media with 2% 
glucose lacking leucine (SD (L-)) was used to inoculate 5mL of synthetic complete media 
with 2% galactose lacking leucine (SCgal (L-)) to OD600=0.1 and incubated overnight at 
30°C (250 rpm). Overnight cultures of strain PPY951-952 in synthetic complete media 
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with 2% glucose lacking tryptophan (SD (W-)) was used to inoculate 5mL of synthetic 
complete media with 2% galactose lacking tryptophan (SCgal (W-)) to OD600=0.1 and 
incubated overnight at 30°C (250 rpm). Overnight cultures of strain PPY953-954 in 
synthetic complete media with 2% glucose lacking histidine (SD (H-)) was used to 
inoculate 5mL of synthetic complete media with 2% galactose lacking histidine (SCgal 
(H-)) to OD600=0.1 and incubated overnight at 30°C (250 rpm). Total RNA for all 
cultures was extracted using a RNeasy Mini Kit (Qiagen) following the manufacturer’s 
protocol for isolation from yeast using 3x10
7
 cells per culture. RNA quantity was 
measured using a NanoDrop Lite. 1 µg of total RNA was taken from each strain and 
converted into cDNA using QuantiTect® reverse transcription kit (Qiagen) using 
manufacturer’s instructions. Relative expression levels of GFP were quantified using 
QuantiTect® SYBR Green PCR kit (Qiagen) using manufacturer’s instructions for 
LightCyclers 1.x and 2.0 with 150ng cDNA per reaction. Duplicate reactions were set up 
for each strain. Quantification was completed using a StepOnePlus Real-time PCR 
system (Applied Biosystems) with primers AME443/AME444 (GTPCH), 
AME441/AME442 (PTPS), AME445/AME446 (SR), and ACT-F/ACT-R. Cycling 
conditions: 15 min activation at 95°C followed by 40 cycles of 15 s 95°C, 15 s 57°C, and 
15 s 72°C. ACT1, a gene that encodes actin, was used to normalize the amount of the 
mRNA for the gene of interest in all samples. 
2.5.15 Amino Acid Limiting Experiments 
Overnight cultures of strain PPY649 and PPY646 in synthetic media containing 2% 
glucose and lacking histidine, leucine, uracil, and tryptophan (SD (HWUL-)) was used to 
inoculate 5mL of synthetic media containing 2% galactose and lacking histidine, leucine, 
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uracil, and tryptophan (SCgal (HWUL-)) to OD600=0.1. Tryptophan was added to strain 
PPY649 (final concentrations 0-640 mg/L) and tyrosine was added to strain PPY646 
(final concentrations 30-960 mg/L). Cultures were incubated for 136 hours at 30°C (250 
rpm). After incubation, cultures were centrifuged for 5 min at 3230 x g. Supernatant was 
removed, filtered and analyzed via LC/MS analysis. 5-chlorotryptamine was used as an 
internal standard.  
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CHAPTER 3. Medium-throughput Screen of Microbially Produced 
Serotonin via a G-Protein-Coupled Receptor-based 
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Ehrenworth, A.M., Claiborne, T., and Peralta-Yahya, P. Medium-throughput Screen of 
Microbially Produced Serotonin via a G-Protein-Coupled Receptor-based Sensor 
Biochemistry, accepted. DOI: 10.1021/acs.biochem.7b00605 Unpublished work 
copyright 2017 American Chemical Society. 
3.1 Abstract 
Chemical biosensors, for which chemical detection triggers a fluorescent signal, have 
the potential to accelerate the screening of noncolorimetric chemicals produced by 
microbes, enabling the high-throughput engineering of enzymes and metabolic pathways. 
Here, we engineer a G-protein-coupled receptor (GPCR)-based sensor to detect serotonin 
produced by a producer microbe in the producer microbe’s supernatant. Detecting a 
chemical in the producer microbe’s supernatant is nontrivial because of the number of 
other metabolites and proteins present that could interfere with sensor performance. We 
validate the two-cell screening system for medium-throughput applications, opening the 
door to the rapid engi-neering of microbes for the increased production of serotonin. We 
focus on serotonin detection as serotonin levels limit the microbial production of 
hydroxystrictosidine, a modified alkaloid that could accelerate the semisynthesis of 
camptothecin-derived anticancer pharmaceuticals. This work shows the ease of 
generating GPCR-based chemical sensors and their ability to detect specific chemicals in 
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complex aqueous solutions, such as microbial spent medium. In addition, this work sets 
the stage for the rapid engineering of serotonin-producing microbes. 
3.2 Introduction 
 Detecting and quantifying the levels of noncolorimetric chemicals synthesized by 
engineered microbes relies on low-throughput chromatography-based technologies (~100 
samples per day), such as gas chromatography and liquid chromatography with mass 
spectrometry (LC/MS). Chemical biosensors that convert a chemical signal into a 
fluorescent output enable the use of high-throughput screening technologies (up to 10
7
 
samples per day), such as microtiter plates or fluorescence activated cell sorting (FACS), 
for chemical detection. Such throughput can fast-track the engineering of microbes for 
the synthesis of noncolorimetric chemicals to achieve industrially relevant titers, yields, 
and productivities. 
Previously, we engineered the yeast Saccharomyces cerevisiae for the production of 
the modified monoterpene indole alkaloid hydroxystrictosidine, a potential advanced 
intermediate in the semisynthesis of the anticancer agents irinotecan and topotecan.
1,2
 
Specifically, the engineered yeast converts simple sugars to serotonin, and strictosidine 
synthase couples serotonin with exogenously added secologanin to produce 
hydroxystrictosidine. As secologanin is fed to the engineered strain for the synthesis of 
hydroxystrictosidine, serotonin becomes the de facto rate-limiting substrate in the 
process. Serotonin is not colorimetric and LC/MS was used for the detection and 




Interested in engineering an improved serotonin-producing microbe, we sought to 
develop a serotonin biosensor to detect serotonin in the spent medium of a serotonin-




 samples per day) (Figure 
3.1). We prefer to detect serotonin non-invasively in the spent medium of the serotonin 
producer microbe as this setup allows us to decouple serotonin production from serotonin 
sensing. Advantages of such a system include (1) the use of the same sensor as serotonin 
titers increase by simply diluting the spent medium so that the serotonin concentration is 
in the linear range of the sensor, (2) enabling the use of random, genomewide 
mutagenesis strategies to engineer the producer microbe without detrimental effects on 
the sensor function, and (3) the future potential to high-throughput screen producer 
microbes by encapsulating the producer and sensor cells and using FACS.   
Recently, we developed G-protein-coupled receptor (GPCR)-based sensors in yeast 
by expressing a GPCR known to bind the chemical of interest on the yeast cell surface 
and coupling it to the yeast mating pathway, resulting in the expression of green 
fluorescent protein (GFP) upon chemical detection.
3
 The proof-of-principle GPCR-based 
sensor detected decanoic acid using the GPCR OR1G1. We hypothesized that simply 
swapping OR1G1 with a GPCR known to bind serotonin, keeping the rest of the sensor 
cell intact, would result in a serotonin sensor. Additionally, previous GPCR-based 
sensors have not been shown (1) to detect specific analytes in complex medium, such as 
microbial spent medium, or (2) to have the statistical parameters necessary to be used in 
medium-throughput screening applications. These challenges need to be addressed prior 
to using GPCR-based sensors for the rapid engineering of microbes for the production of 
chemicals, in this particular case serotonin. 
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Figure 3.1. Detecting microbially produced serotonin via the G-protein coupled 
receptor (GPCR)-based serotonin sensor. (A) Engineered yeast produces serotonin 
from simple sugars.
1
 (B) Serotonin sensor. A known human serotonin GPCR (HTR) 
is expressed in a GPCR-based sensor cell (W303 ∆ste2, ∆far1, ∆sst2).
3
 Binding of 
serotonin to HTR on the cell surface stimulates the yeast mating pathway (yellow), 
ultimately activating expression of the reporter gene, green fluorescent protein 
(GFP). (C) The serotonin sensor cell detects serotonin in the spent medium of the 
serotonin producer cell in a medium-throughput fashion (96-well plates). 
Abbreviations: TPH, tryptophan hydroxylase; DDC, aromatic amino acid 
decarboxylase; BH4, tetrahydrobiopterin; BH4-OH, pterin 4a-carbinolamine. 
Of the 12 serotonin GPCRs expressed in humans,
4
 GPCRs 5-HT1a and 5-HT1d have 
been previously used to generate serotonin sensors in yeast.
5,6
 Using a yeast/human Gα 
subunit chimera (Gpa1/Gαi3) and the lacZ reporter gene, the 5-HT1a-based sensor had a 
KD of 7 μM while the 5-HT1d-based sensor had a KD of 2 μM; albeit, no dynamic range 
was reported.
6
 The 5-HT1a-based and the 5-HT1d-based sensors showed negligible or no 
response when using the native yeast Gα subunit, Gpa1.
6
 More recently, a 5-HT1a-based 
sensor using Gpa1 and GFP as the reporter gene resulted in a 1.25-fold increase in the 
intensity of the signal after activation with serotonin and a KD of ~50 μM.
5
 Swapping 
Gpa1 for Gpa1/Gαi3 and GFP for ZsGreen resulted in a sensor with a ~4-fold increase in 
the intensity of signal after activation with serotonin and a KD of ~20 μM
5
. Given that our 
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previously engineered serotonin-producing strain yielded 5 mg of serotonin/L, we needed 
a sensor with a KD of ~28 μM and with a significant increase in the intensity of signal 
after activation.  
Here, we engineer a GPCR-based serotonin sensor that can detect serotonin in 
microbial spent medium. We demonstrate that, after medium optimization, the sensor can 
be used in 96-well plate format with reliable statistical parameters that set the stage for 
the sensor to be used in the evolution of an improved serotonin-producing microbe. The 
optimization of the spent medium and 96-well plate sensor validation workflow presented 
in this work are likely to mirror optimizations that would be needed to adapt other 
GPCR-based sensors for the detection of microbially produced chemicals in the spent 
medium in a medium throughput fashion.   
3.3 Results 
3.3.1 Serotonin Sensor 
Previously, we engineered a GPCR-based sensor strain (W303 Δfar1, Δsst2, Δste2, 
pRS415-PFig1-GFP) that relies on Gpa1 to transmit the signal from a GPCR on the cell 
surface to the yeast mating pathway, which ultimately activates expression of a reporter 
gene. Using this sensor strain, we screened six known human serotonin GPCRs: 5-HT1a, 
5-HT1d, 5-HT2b, 5-HT4, 5-HT5a, and 5-HT6. GPCR 5-HT4 has at least 11 known isoforms, 
and all but one vary at the C-terminus,
7
 which is where the GPCR interacts with the Gα 
subunit. We tested 5-HT4 isoform b, the canonical isoform. GPCR 5-HT6 has two 
isoforms; however, only one is functional,
8
 and we tested the functional isoform. All 
other serotonin GPCRs tested only have one isoform.
8
 Without any changes to the 
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original sensor strain, expression of 5-HT4 isoform b in the sensor strain resulted in a ~3-
fold increase in the intensity of the signal after activation upon exogenous addition of 100 
mg/L serotonin (Figure 3.2A). The 5-HT4 GPCR is found in both the nervous system and 
the gut,
4
 where 90% of the body’s serotonin is found.
9
 No response was seen upon 
expression of the reporter gene in the sensor strain in the absence of 5-HT4, confirming 
that 5-HT4 is needed for serotonin detection (Figure 3.3). No response was seen upon 
expression of 5-HT4 in the sensor strain in the absence of the reporter gene, confirming 
that serotonin was not increasing the cell autofluorescence levels (Figure 3.3). A dose-
response curve of the 5-HT4-based serotonin sensor showed a KD of 8.1 mg/L (46 μM) 
with a linear range of 0.7-10 mg/L and a maximum 2.7-fold increase in the intensity of 
the signal after activation (Figure 3.2B; Figure 3.4). As the titers of microbially produced 
serotonin (~5 mg/L) land in the middle of the linear range of the serotonin sensor, no 
further engineering of the linear range was required. To increase the dynamic range of the 
5-HT4–based sensor, we swapped GFP for ZsGreen. In our plasmid-based reporter 
system, ZsGreen showed greater colony-to-colony variability in the increase in the 
intensity of the signal after serotonin activation (from 6.5- to 20-fold) than GFP did (from 
2- to 3-fold) (Figure 3.5). To make a more reliable sensor and reduce the number of false 
positives in our medium-throughput screen, we kept GFP as the reporter gene.  
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Figure 3.2. Serotonin sensor engineering. (A) Screening of serotonin GPCRs in the 
GPCR-based sensor strain for response to serotonin in fresh medium. (B) 5-HT4-
based serotonin sensor dose-response curve in fresh medium with exogenously 
added serotonin. (C) Detection of serotonin exogenously added to plain yeast spent 
medium. The plain yeast cell carries four blank plasmids instead of the serotonin 
pathway. (D) 5-HT4-based serotonin sensor dose-response curve in plain yeast spent 
medium with exogenously added serotonin. All experiments were performed in 
triplicate, and the error bars represent the standard deviation from the mean. In all 
cases, the fluorescence was normalized to the sensor response in the absence of 




Figure 3.3. Serotonin sensor controls. Response to serotonin in cells expressing 
either reporter construct (PFIG1-GFP) and not 5-HT4 or 5-HT4 and not PFIG1-GFP. 
Experiments were carried out in triplicate and the error bars represent the 
standard deviation from the mean. Fluorescence was normalized to the response of 









Figure 3.5. Serotonin sensor colony-to-colony variation when using GFP or ZsGreen 
as the reporter gene. (A) Serotonin sensor response of four different colonies using 
GFP as the reporter gene. (B)   Serotonin sensor response of three different colonies 
using ZsGreen as the reporter gene. Experiments were carried out in triplicate and 
the error bars represent the standard deviation from the mean. Fluorescence was 
normalized to the response of the sensor to 0 mg/L serotonin. 
3.3.2 Detection of Exogenously Added Serotonin in Plain Microbial Spent Medium 
As the 5-HT4-based sensor detected exogenously added serotonin in fresh medium, 
we determined if the sensor could also detect exogenously added serotonin in the spent 
medium of plain yeast, i.e. yeast carrying empty plasmids rather than the serotonin 
production pathway (Figure 3.2C). Indeed, the sensor detected serotonin with a KD of 6.1 
mg/L, a linear range of 0.8-5 mg/L, and a 1.7-fold increase in the intensity of the signal 
after activation (Figure 3.2D). Interestingly, the linear and dynamic range of the sensor 
decreased when serotonin was detected in spent rather than fresh medium. We speculate 
that the presence of yeast produced metabolites or the fact that some nutrients were 
consumed by the cell over time disturbed either the binding of serotonin to 5-HT4 or the 
GPCR-based signaling process. To achieve a larger dynamic range to better distinguish 
producer microbes yielding different levels of serotonin, we examined the compositional 
differences between fresh and spent medium to adjust the nutritional constituents of the 
spend medium to optimize serotonin detection.   
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3.3.3 Effect of Nutrient Composition on Serotonin Sensing 
The glucose concentration can affect the yeast mating pathway signaling process.
10
 
As the serotonin-producing microbe uses galactose as the carbon source
1
, we determined 
the effect of different glucose and galactose concentrations on serotonin sensing in fresh 
medium. The highest serotonin sensor signal intensity was achieved in the presence of 
2% glucose, the standard glucose concentration in yeast medium (Figure 3.6A). In the 
absence of glucose and presence of galactose or in the absence of both glucose and 
galactose, no sensor signal was observed, demonstrating the dependence of the serotonin 
sensor on glucose. Serotonin detection was restored upon addition of 0.4% glucose. Next, 
we analyzed the difference in nutrient composition between the sensor medium, which 
lacks histidine and leucine, and the serotonin producer medium, which lacks tryptophan 
and uracil in addition to histidine and leucine. In the absence of tryptophan and in the 
presence of 100 mg/L serotonin, we saw no sensor response (Figure 3.6B). The sensor 
response to serotonin was rescued upon addition of 20 mg/L tryptophan, the standard 
tryptophan concentration in fresh medium. Further addition of 20 mg/L uracil, the 
standard uracil concentration in fresh medium, had a slightly positive effect on serotonin 
detection. We attribute the improvement in sensor performance upon addition of uracil to 
the reduced metabolic burden on the sensor. To ensure that the serotonin sensor responds 
to serotonin and not tryptophan or the pathway intermediate hydroxytryptophan, we 
measured the serotonin sensor response to each of these compounds in the presence and 
absence of tryptophan (Figure 3.6C). Additionally, we measured the sensor response to 5-
hydroxyindoleacetic acid (5-HIAA), a product of serotonin catabolism (Figure 3.7). The 
sensor showed no response in the presence of up to 100 mg/L tryptophan, 
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hydroxytryptophan, or 5-HIAA. The sensor responded to serotonin only in the presence 
of tryptophan. We speculate that tryptophan is acting as an allosteric modulator of 5-HT4, 
helping to enhance the sensor signal. Indeed, allosteric modulation of the serotonin-
mediated response has been seen in mammalian cells with 5-HT2A in the presence of 
oleamide
11
 and 5-HT1B/1D desensitization in the presence of the peptide moduline.
12
 More 
generally, ions, lipids, amino acids, and peptides have been shown to be modulators of 
GPCR activity.
13
 Taking these results into account, we adjusted the plain yeast spent 
medium to 0.4% glucose and added 100 mg/L tryptophan before serotonin detection. 
After adjustment, the linear range of the sensor increased from 0.8-5 to 1-10 mg/L 
(Figure 3.6D).  Although the increase in the dynamic range was not as dramatic (2-fold 
vs 1.7-fold in non-adjusted spent media), the KD stayed the same at ~6.1 mg/L. The 
improvement in the serotonin sensor linear range makes it suitable to screen for 
microbially produced serotonin.  
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Figure 3.6. Serotonin sensor optimization. (A) Serotonin sensor dependence on 
glucose. (B) Serotonin sensor dependence on uracil and tryptophan. (C) Sensor 
response to serotonin pathway intermediates tryptophan, hydroxytryptophan, and 
serotonin in the presence or absence of tryptophan. Abbreviations: Trp, 
tryptophan; 5-HTP, hydroxytryptophan; Sero, serotonin. Experiments depicted in 
panels A-C were performed in fresh medium. (D) Dose-response curve of the 
serotonin sensor detecting serotonin exogenously added to plain yeast spent medium 
that had been adjusted for glucose (0.4%) and tryptophan (100 mg/L) content. All 
experiments were performed in triplicate and the error bars represent the standard 
deviation from the mean. In all cases, fluorescence was normalized to the response 
of the sensor to no serotonin or no pathway intermediates. Inset shows the linear 




Figure 3.7. Serotonin sensor response to serotonin (Sero) and 5-hydroxyindoleacetic 
acid (5-HIAA). Samples fed 100 mg/L serotonin were run in duplicate. All other 
experiments were done in triplicate and the error bars represent the standard 
deviation from the mean. Fluorescence was normalized to the response of the sensor 
to no serotonin or 5-HIAA. 
3.3.4 Detecting Microbially Produced Serotonin in a Medium-throughput Assay 
The serotonin sensor resulted in a 1.3-fold increase in the intensity of the signal after 
activation when detecting microbially produced serotonin in the producer’s spent 
medium. Upon adjusting the glucose and tryptophan concentrations of the producer’s 
spent medium, we saw an additive improvement in response resulting in a 1.8-fold 
increase in the intensity of the signal after activation (Figure 3.8A-C). To validate the use 
of the serotonin sensor for medium-throughput screening applications using 96-well 
plates, we performed a 3 day plate uniformity experiment
14
 in both fresh medium and 
producer spent medium adjusted with tryptophan and glucose (Figure 3.8D-F). Using two 
statistical parameters for assay acceptance, a Z factor of > 0.5
15
 and coefficient of 
variation (CV) of < 10%,
16
 the assay met the criteria for use in both media (average Z 
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factor of 0.7, average CV of 4.9%). We did see a slight interplate drift, which could be 
optimized by accelerating the collection time or staggering the activation times. 
 
Figure 3.8. Detection of microbially-produced serotonin. (A) Schematic of 
microbially produced serotonin detection. (B) Serotonin sensor response upon 
incubation with spent medium from plain yeast (PPY1391) and the serotonin 
producer strain (PPY741). Experiments were performed in triplicate, and error 
bars represent the standard deviation from the mean. The fluorescence was 
normalized to the response in nonproducer spent medium for each condition. (C) 
Representative LC/MS (multiple-reaction monitoring) traces of the spent media 
from strains PPY1391 (gray) and PPY741 (purple). Shown is the serotonin 
transition from 176.80 to 160.00. (D) Schematic of the medium-throughput 
serotonin screen. (E and F) Serotonin sensor response in fresh or spend medium, 





We have developed a serotonin sensor capable of detecting microbially produced 
serotonin in the producer spent medium that has been validated for use in a medium-
throughput 96-well plate assay. To generate a serotonin sensor, we screened known 
human serotonin GPCRs by expressing them in the yeast sensor strain for serotonin 
detection. No other genetic modifications to the sensor strain were needed, demonstrating 
the ease with which GPCR-based chemical sensors can be generated. To use the 
serotonin sensor for the rapid engineering of chemical-producing microbes, we 
demonstrate that the sensor can detect serotonin in the spent medium of the serotonin 
producer microbe and has the statistical parameters necessary to be used in a medium-
throughput 96-well plate screen. The nutritional adjustments of the spent medium 
revealed in this work will likely be needed when using other GPCR-based sensors for the 
detection of chemicals in microbial spent medium. The 96-well plate workflow is 
applicable to other GPCR-based medium-throughput screens, and the workflow should 
also be amenable to the 384-well plate format pending assay validation. 
Upon detection of microbially produced serotonin in the producer microbe’s spent 
medium, the sensor response was ~2-fold. Although the signal was statistically 
significant (P =0.005), the sensor response would benefit from improvement. Coupling of 
5-HT4 to the yeast Gα subunit could be optimized by swapping 5-HT4’s cytoplasmatic 
domain with that of the S. cerevisiae GPCR Ste2 or using Gpa1/human Gα chimeras.
17
 
However, these strategies do not always result in an improvementin the signal.
3
 Using 
ZsGreen as the reporter gene and integrating it into the chromosome should also increase 
the intensity of the sensor signal.
5
 Alternatively, a feed forward loop could be introduced 
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into the sensor strain to increase the intensity of the signal only in the presence of 
serotonin. Such a loop could generally increase the intensity of the signal of GPCR-based 
sensors. Finally, although the linear range of the 5-HT4–based serotonin sensor is narrow, 
the two-cell screening system allows for the producer microbe supernatant to be diluted 
so that the serotonin concentration lands in the linear range of the sensor.  
Validation of the sensor for two key statistical parameters, Z factor and CV, shows 
that the sensor is suitable for 96-well plate screening, and it is now poised to be used in 
the engineering of improved serotonin-producing microbes. Given that serotonin is the 
limiting substrate in the production of hydroxystrictosidine, a potential advanced 
intermediate in the semisynthesis of the anticancer agents irinotecan and topotecan, the 
medium-throughput serotonin assay will likely enable the future increased production of 
hydroxystrictosidine as well as other modified monoterpene indole alkaloids. 
3.5 Materials and Methods 
3.5.1 Reagents 
Serotonin hydrochloride was purchased from TCI (S0370). Tryptophan was 
purchased from Sigma (T0254). Hydroxytryptophan was purchased from Selleck 
Chemicals. 5-chlorotryptamine was from Ark Pharm, Inc. (AK-32281). 5-
Hydroxyindoleacetic acid was purchased from Sigma (H8876). 
3.5.2 Exogenous Serotonin Detection in Fresh Media 
Overnight cultures of strains expressing serotonin receptors (PPY1384-
7,PPY1390,PPY1444-5) in synthetic complete media lacking histidine and leucine with 
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2% glucose (SCglu(HL-)) were used to inoculate 20 mL of fresh SCglu(HL-) to an 
OD600= 0.06. After incubation at 15°C (150 rpm) for 18 h for receptor expression, the 
sensor cells were centrifuged, resuspended in 3 mL water, and used to inoculate 200 µL 
of SCglu(HL-) to OD600= 0.1. Serotonin was added to a final concentration of 0-300 
mg/L. Plates were covered with Breathe Easy Sealing Membrane (Electron Microscopy 
Sciences) and samples were incubated for 4 h at 30 °C (250 rpm) for serotonin sensing. 
Fluorescence from 5,000 cells was measured using a Millipore Guava easyCyte HT flow 
cytometer. Data analysis was completed using FlowJo. For initial receptor screening and 
5-HIAA screening, PPY1385 was used to express 5-HT4. For subsequent experiments 
PPY1390, which expresses mCherry in addition to 5-HT4, was used. 
3.5.3 Serotonin Detection Controls 
Overnight cultures of strains PPY1388 and PPY1389 in SCglu(HL-) were used to 
inoculate 20 mL of fresh SCglu(HL-) to an OD600= 0.06 and incubated for 18 h at 15°C 
(150 rpm). The cells were centrifuged, resuspended in 3 mL water, and used to inoculate 
200 μL of fresh SCglu(HL-) to OD600 = 0.1 in flat-bottom 96-well plates. Serotonin was 
added to a final concentration of 0 or 100 mg/L, plates were covered with Breathe Easy 
Sealing Membrane, and samples were incubated for 4 h at 30 °C (250 rpm). Fluorescence 
from 5,000 cells was measured using a Millipore Guava easyCyte HT flow cytometer. 
Data analysis was completed using FlowJo. 
3.5.4 Colony Variation Using GFP vs. ZsGreen as Reporter Genes 
Overnight cultures of multiple colonies of the serotonin sensor strain carrying GFP 
(PPY1390) or ZsGreen (PPY1446) as the reporter gene in SCglu(HL-) were used to 
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inoculate 100 or 20 mL, respectively, of fresh in SCglu(HL-) to an OD600= 0.06 and 
incubated for 18 h at 15°C (150 rpm). The cells were centrifuged, resuspended in 20 or 3 
mL water, respectively, and used to inoculate 200 μL of SCglu(HL-) to OD600= 0.1 in 
flat-bottom 96-well plates. Serotonin was added to a final concentration of 0 or 100 
mg/L, plates were covered with Breathe Easy Sealing Membrane, and samples were 
incubated for 4 h at 30 °C (250 rpm). Fluorescence from up to 5,000 cells was measured 
using a Millipore Guava easyCyte HT flow cytometer. Data analysis was completed 
using FlowJo. 
3.5.5 Exogenous Serotonin Detection in Adjusted Fresh Media 
Overnight cultures of PPY1390 in SCglu(HL-) were used to inoculate 100 mL of 
fresh SCglu(HL-) to an OD600= 0.06 and incubated for 18 h at 15°C (150 rpm). The cells 
were centrifuged at 3500 rpm for 10 min, resuspended in 20 mL water, and used to 
inoculate 200 μL of synthetic media with various glucose, galactose, uracil, and amino 
acid contents to OD600= 0.1 in flat-bottom 96 well plates. Serotonin, tryptophan, or 
hydroxytryptophan were added to final concentrations between 0-300 mg/L. Plates were 
covered with Breathe Easy Sealing Membrane and incubated for 4 h at 30°C (250 rpm). 
Fluorescence from 5,000 cells was measured using a Millipore Guava easyCyte HT flow 
cytometer and the data was analyzed using FlowJo. 
Overnight cultures of PPY1385 in SCglu(HL-) were used to inoculate 20 mL of fresh 
SCglu(HL-) to an OD600 = 0.06 and incubated for 18 h at 15°C (150 rpm). The cells were 
centrifuged at 3500 rpm for 10 min, resuspended in 3 mL SCglu(HL-), and used to 
inoculate 5 mL SCglu(HL-) to OD600 = 0.05. Serotonin or 5-hydroxyindoleacetic acid 
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was added to final concentrations of 0 or 100 mg/L. Tubes were incubated for 4 h at 30°C 
(250 rpm). Fluorescence from 10,000 cells was measured using a BD LSR II flow 
cytometer and the data was analyzed using FlowJo. 
3.5.6 Spent Media Preparation 
Overnight cultures of yeast carrying empty vectors (PPY1391) and serotonin-
producing yeast (PPY741) in synthetic media lacking histidine, tryptophan, leucine, and 
uracil with 2% glucose (SCglu(HWLU-)) were each used to inoculate three flasks of 50 
mL of fresh synthetic media lacking histidine, tryptophan, leucine, and uracil with 2% 
galactose (SCgal(HWLU-)) to an OD600 = 0.1. Flasks were incubated for 69 h at 30°C 
(250 rpm) for serotonin production. Cells were centrifuged at 1100 x g for 6 min. 
Samples were taken from each flask and stored at -20°C for sensor and mass 
spectrometry analysis. Remaining spent media for each strain was pooled together for 
sensor validation. 
3.5.7 Exogenous Serotonin Detection in Spent Media 
Resuspended sensor cells were used to inoculate 200 μL of spent media to OD600= 0.1 
in flat-bottom 96 well plates. For adjusted spent media, solutions were added to reach 
final concentrations of 0.4% glucose and/or 100 mg/L tryptophan. For the dose-response 
curve, serotonin was added to final concentrations of 0-300 mg/L. Samples were 
incubated for 4 h at 30°C (250 rpm) for serotonin sensing, data was collected using 
Millipore Guava easyCyte HT flow cytometer and analyzed using FlowJo. 
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3.5.8 Medium-Throughput Serotonin Screening Validation 
Three day plate uniformity experiments were completed using the interleaved-signal 
format
11
. For fresh media, resuspended sensor cells were used to inoculate 200 μL of 
SCglu(HL-) to OD600= 0.1 in flat-bottom 96 well plates. Serotonin was added to final 
concentrations of 300, 6, or 0 mg/L corresponding to maximum, middle, and minimum 
signals, respectively. For spent media, resuspended sensor cells were used to inoculate 
200 μL of spent media from PPY1391 and PPY741 adjusted to 0.4% glucose and 100 
mg/L tryptophan to OD600= 0.1 in flat-bottom 96 well plates. For spent media, maximum, 
middle, and minimum signals referred to PPY741 spent media and 300 mg/L serotonin, 
PPY741 spent media, and PPY1391 spent media, respectively. Spent media was stored at 
4°C over the three-day experiment. Data was collected using Millipore Guava easyCyte 
HT flow cytometer and analyzed using FlowJo. Validation calculations were performed 
using the Excel template provided by Iversen, et al.
11
 using settings for an activation 
study with single replicates. 
3.5.9 Flow Cytometry Data Analysis 
Geometric mean of the GFP-area channel was calculated for each sample using 
FlowJo. All fluorescence values were normalized to basal levels (0 mg/L serotonin or 
non-producer spent media) for all conditions tested. Student T-tests were performed using 
Microsoft Excel. KD and fold increase in signal after activation for dose-response curves 
were obtained by fitting the experimental data to the Hill equation using Igor Pro. The 
lower limit of the linear range was the concentration corresponding to 10% signal 
saturation from the fitted model. The upper limit was determined through linear 
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regression analysis of experimental data until R
2
 was no longer ≥ 0.95. For the adjusted 




3.5.10 Microbially Produced Serotonin Identification 
Multiple Reaction Monitoring (MRM) of serotonin was performed at the Mass 
Spectrometry Facility at Georgia Tech. MRM was done using a Waters Quattro LC Mass 
Spectrometer with a Gemini 2 x 150mm C18 column. LC conditions: Solvent A: 
95%:5%:0.1% water:acetonitrile:formic acid; Solvent B: 100%:0.1% acetonitrile:formic 
acid. Gradient: 7 min at 100%:0% (A:B), 37 min ramp to 0%:100%, 8 min at 0%:100%, 
0.1 min ramp to 100%:0%, and 7.9 min at 100%:0%. Flow rate was 0.2 mL/min. 
Serotonin standard curve was prepared in PPY1391 spent media. 5-Chlorotryptamine was 
used as an internal standard. MRM parameters: serotonin- transition 176.80 → 160.00, 
cone voltage 20V, collision energy 30eV; transition 176.80 → 115.00, cone voltage 20V, 
collision energy 30eV; 5-chlorotryptamine- transition 194.90 → 177.90, cone voltage 
25V, collision energy 10eV; transition 194.90 → 142.80, cone voltage 25V, collision 
energy 30eV. 
3.5.11 Plasmid Construction 
Receptors 5-HT2b, 5-HT4, 5-HT5a, and 5-HT6 were yeast codon optimized, 
commercially synthesized, amplified using primers AME544/AME519, 
AME538/AME519, AME542/AME519, or AME536/AME519, respectively, and cloned 
into pKM111 at BamHI/SacII to generate plasmids pTMC14, pTMC18, pTMC22, and 
pTMC26. Receptors 5-HT1d and 5-HT1a were yeast codon optimized, commercially 
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synthesized, and directly cloned into pKM111 at BamHI/SacII to generate plasmids 
pAME142 and pAME144, respectively. The plasmids were sequence verified using 
primers AME397 and AME105. To construct pESC-PTEF1-5-HT4-PADH1-mCherry-His3 
(pTMC40), mCherry was amplified from pmCherry using primers AME570/AME571, 
cloned into pTMC18 at SacI/NotI, and sequence verified using primer AME229. To 
construct pRS415-PFIG1-ZsGreen-Leu2 (pAME143), ZsGreen was yeast codon optimized, 
commercially synthesized, amplified using primers AME519/AME648, and cloned into 
pKM586 at NheI/NcoI. The construct was sequence verified using primer AME105. 
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CHAPTER 4. Quantifying the Efficiency of Saccharomyces 
cerevisiae Translocation Tags 
Reproduced with permission from: 
Ehrenworth, A.M., Haines, M.A., Wong, A. and Peralta-Yahya, P. Quantifying the 
Efficiency of Saccharomyces cerevisiae Translocation Tags Biotechnology and 
Bioengineering DOI: 10.1002/bit.26376 Copyright 2017 John Wiley and Sons. 
4.1 Abstract 
Compartmentalization of metabolic pathways into organelles of the yeast 
Saccharomyces cerevisiae has been used to improve chemical production. Pathway 
compartmentalization aids chemical production by bringing enzymes into close proximity 
to one another, placing enzymes near key starting metabolites or essential co-factors, 
increasing the effective concentration of metabolic intermediates, and providing a more 
suitable chemical environment for enzymatic activity. Although several translocation tags 
have been used to localize enzymes to different yeast organelles, their translocation 
efficiencies have not been quantified. Here, we systematically quantify the translocation 
efficiencies of the ten commonly used S. cerevisiae tags by localizing green fluorescent 
protein into three yeast organelles: the mitochondrion (4 tags), the vacuole (3 tags), and 
the peroxisome (3 tags). Further, we investigate whether plasmid copy number or mRNA 
levels vary with tag translocation efficiency. Quantification efficiencies of S. cerevisiae 
translocation tags provides an important resource for bioengineering practitioners when 
choosing a tag to compartmentalize their desired protein. Finally, these efficiencies can 
be used to determine the percentage of enzyme compartmentalization and, thus, help 
better quantify effects of compartmentalization on metabolic pathway efficiency.  
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4.2 Introduction 
Compartmentalization of metabolic pathways is an important strategy to increase 
chemical production
1
. Pathway compartmentalization aids chemical production by 1) 
bringing enzymes into close proximity of one another, enabling the handing of 
intermediates from one active site to another one, 2) placing enzymes near key 
metabolites or essential co-factors, 3) increasing the effective concentration of pathway 
intermediates, thus accelerating reaction rates, and 4) sometimes providing a more 
suitable chemical environment for enzymatic activity. Enzyme compartmentalization has 




, and in the yeast 
Saccharomyces cerevisiae, an important chassis for chemical production due to its 
robustness to industrial conditions
5
. The S. cerevisiae mitochondrion has been leveraged 






. Enzymes localized to the 
mitochondria gain proximity to the electron transport chain and key metabolites, such as 
acetyl-CoA and citric acid cycle intermediates. Targeting enzymes to the S. cerevisiae 
vacuole has been exploited for the production of methyl halides, by capitalizing on the 
accumulation of halide ions and the co-factor S-adenosyl methionine
11
. Enzyme 
localization to the vacuole could also take advantage of its low pH, which may provide a 
better environment for some enzymes, such as plant alkaloid pathway enzymes
12
. The S. 





, and fatty acid-derived chemicals
15
. Enzyme 
localization to the S. cerevisiae peroxisome takes advantage of fatty acid degradation 
intermediates. Additionally, the peroxisome may provide a more suitable environment for 




Several S. cerevisiae translocation tags have been used to localize proteins to the 
mitochondrion, vacuole and peroxisome. Despite the extensive knowledge on the 
mitochondrial, vacuolar, and peroxisomal tags’ translocation mechanisms, there is no 
quantitative data on their translocation efficiencies, thus making the choice of 
translocation tags for metabolic engineering applications arbitrary. We hypothesized that 
translocation tags with different translocation mechanisms have different efficiencies. 
Here, we quantify the translocation efficiencies of four mitochondrial, three vacuolar, and 
three peroxisomal tags. The data presented in this work will enable metabolic engineers 
to rationally choose translocation tags for the compartmentalization of metabolic pathway 
enzymes to yeast organelles and to understand the limitations of the chosen tag. Further, 
the measured efficiencies of these tags will aid in approximating the percentage of 
protein localized to the desired compartment. This will allow more than yes/no 
predictions of whether a protein or a pathway has been localized to a compartment, and 
will instead enable calculation of the percentage of protein or pathway localized.  
4.3 Results 
To quantify the efficiency of translocation tags we fused enhanced green fluorescent 
protein (GFP) to ten commonly used S. cerevisiae tags: four mitochondrial tags, three 
vacuolar tags, and three peroxisomal tags. Each of tag-GFP fusions was expressed from 
the strong galactose-inducible promoter PGAL1 in either a single- or a multi-copy plasmid. 
Using confocal microscopy, we determined the effectiveness of the translocation tags to 
localize GFP. To determine if the translocation efficiency was cargo dependent, we also 
visualized the effectiveness of the translocation tags to localize mKate2, a fluorescent 




, we ensured that pH difference did not affect our observation of GFP 
localization to the mitochondria (pH=7.5
18
) and peroxisomes (pH=8
19
) by using pH=7 
media, resulting in a cytosol pH~7
20
.  Likewise, we ensured that pH difference did not 
affect our observation of GFP localization to the vacuole (pH=6
21
) by using pH=4.5 




Figure 4.1. Alignment of eGFP and mKate2 created with Clustal Omega. 
4.3.1 Localization to the Mitochondria 
Mitochondrial presequence tags work by interacting with the Translocase of the Outer 
Membrane (TOM) complex
22,23
. We chose mitochondrial translocation tags based on 





ability to bind Tom20 (THSP60
25
), or their commercial use (TPDA1
26
). To identify the 
mitochondria we used MitoTracker Red CMXRos, which localizes to the mitochondrial 
matrix. We found that GFP localization to the mitochondria is tag dependent and 
independent of whether GFP was expressed from a single- or a multi-copy plasmid. 
TCOX4-GFP had the highest mitochondria translocation efficiency at ~78% (Figure 4.2). 
THSP60, TPDA1, and TOLI1 fused GFP localized to the mitochondria and the cytosol almost 
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evenly, similarly to the localization pattern seen with untagged GFP. TCOX4-mKate2 
showed similar results to TCOX4-GFP (Figure 4.3). Interestingly, THSP60 and TPDA1 fused 
mKate2 did localize to the mitochondria efficiently, which was not the case with the GFP 
cargo. Thus, mitochondria translocation efficiency using presequences is context 
dependent, confirming a phenomenon previously seen
27
 and attributed to protein 
structure
28
. TOLI1-mKate2 showed no fluorescence, however we attribute this to the low 




Figure 4.2. Mitochondrial localization of GFP. a. Schematic of GFP mitochondrial 
localization. b. Table of mitochondrial translocation tags used in this study. c. 
Translocation efficiency of untagged and tagged GFP to the mitochondrion in GFP 
positive cells with average GFP fluorescence. Percent of GFP localized to the 
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mitochondrion is the ratio of the mean GFP fluorescence in the mitochondrion over 
the mean GFP fluorescence of the mitochondria and cytosol. A 50% distribution 
means equal distribution in the organelle and the cytosol. Error bars represent 
standard deviation of 18-35 cells. d, e. Confocal microscope images of GFP positive 
cells with average fluorescence from single-copy (d) or multi-copy (e) plasmids 
showing separate images for the mitochondrial dye MitoTracker Red CMXRos, 
GFP, bright field, and merged images. 
 
Figure 4.3. Mitochondrial localization of mKate2. Confocal microscope images of 
mKate2 positive cells with average fluorescence from multi-copy (left) or single-copy 
(right) plasmids showing separate images for mKate2, bright field, and merged 
images. 
4.3.2 Localization to the Vacuole 
The vacuole can be targeted directly from the cytosol (aminopeptidase pathway)
30
 or 
via the secretory pathway
31
, either through pre-vacuolar compartments (carboxypeptidase 
Y pathway) or directly from the Golgi (alkaline phosphatase pathway). We selected the 
vacuolar translocation tags commonly used for each vacuolar targeting mechanism: pre-
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vacuolar compartments (carboxypeptidase Y: TPRC1
32
), direct translocation from the 
Golgi (alkaline phosphatase: TPHO8
33
), and direct translocation from the cytosol 
(aminopeptidase I: TAPE1
34
). To identify the vacuole, we used FM4-64 stain, which 
localizes to the vacuolar membrane. Similar to mitochondrial tags, localization to the 
vacuole is tag dependent and plasmid copy number did not affect the percentage of GFP 
localized to the vacuole (Figure 4.4). TPRC1-GFP had the highest translocation efficiency 
to the vacuole at ~75%. TAPE1 and TPHO8 did not localize GFP to the vacuole, with ~70% 
of the GFP localized to the cytosol, similar to the localization pattern of untagged GFP. 
TAPE1-mKate2 and TPHO8-mKate2 had a similar localization pattern to untagged GFP 
(Figure 4.5) and TPRC1-mKate2 did not show fluorescence, which we attribute to the low 
brightness compared to GFP
29
. Based on this data, we conclude that translocation to the 
vacuole via pre-vacuoles is the most efficient targeting mechanism. 
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Figure 4.4. Vacuolar localization of GFP. a. Graphical representation of vacuolar 
localization. b. Table of vacuolar translocation tags used in this study. c. 
Quantitative localization of untagged and tagged GFP to the vacuole in GFP positive 
cells with average fluorescence.  Percent GFP localized to the vacuole is the ratio of 
the mean GFP fluorescence in the vacuole over the mean GFP fluorescence of the 
vacuole and cytosol. A 50% distribution means equal distribution in the organelle 
and the cytosol. Error bars represent standard deviation of 15-50 cells. d, e. 
Confocal microscope images of GFP positive cells with average fluorescence from 
single-copy (d) or multi-copy (e) plasmids showing separate images for the vacuolar 
dye FM 4-64, GFP, bright field, and merged images. 
 133 
 
Figure 4.5. Vacuolar localization of mKate2. Confocal microscope images of mKate2 
positive cells with average fluorescence from multi-copy (left) or single-copy (right) 
plasmids showing separate images for mKate2, bright field, and merged images. 
4.3.3 Localization to the Peroxisome 
Translocation to the peroxisome can be achieved using two types of peroxisomal 
targeting sequences (PTSs): C-terminal PTS1, which binds the Pex5 receptor, and N-
terminal PTS2, which binds the Pex7 receptor
35
. We chose a canonical (TLUC
36
) and a 
non-canonical (TCAT
37
) PTS1 tag and a PTS2 tag (TPOT1
38
). Given the lack of stains to 
identify the peroxisome, we used peroxisome apparent localization based on the GFP 
signal and bright field images. Similarly to mitochondrial and vacuolar tags, translocation 
to the peroxisomes was dependent only on the translocation tag and not on the plasmid 
copy number (Figure 4.6). Both PTS1 tags (TLUC and TCAT) resulted in a GFP 
translocation efficiency to the peroxisome of ~99% and 93%, respectively. TPOT1-GFP 
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localized to the peroxisome and the cytosol almost evenly. mKate2 translocation 
efficiencies with TLUC and TCAT were comparable to GFP translocation efficiencies 
(Figure 4.7). Based on these results, C-terminal PTS1 translocation tags TLUC and TCAT 
are more efficient at translocating payloads to the peroxisomes than the PTS2 tag TPOT1. 
While PTS1 is highly efficient as a tripeptide tag, recent work has resulted in enhanced 




Figure 4.6. Peroxisomal localization of GFP. a. Schematic of GFP peroxisome 
localization. b. Table of peroxisomal translocation tags used in this study. c. 
Translocation efficiency of tagged GFP to the peroxisome in GFP positive cells with 
average GFP fluorescence.  Percent of GFP localized to the peroxisome is the ratio 
of the mean GFP fluorescence in the peroxisome over the mean GFP fluorescence of 
the peroxisome and cytosol. A 50% distribution means equal distribution in the 
organelle and the cytosol. Error bars represent standard deviation of 20-28 cells. d, 
e. Confocal microscope images of GFP positive cells with average fluorescence from 
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single-copy (d) or multi-copy (e) plasmids showing separate images for GFP, bright 
field, and merged images. 
 
Figure 4.7. Peroxisomal localization of mKate2. Confocal microscope images of 
mKate2 positive cells with average fluorescence from multi-copy (left) or single-copy 
(right) plasmids showing separate images for mKate2, bright field, and merged 
images. 
4.3.4 Analysis of mRNA and GFP expression 
Concerned about the translocation tag disturbing the cargo mRNA levels, and 
potentially having an impact on the translocation efficiencies, we measured the relative 
mRNA levels of tagged and untagged GFP when expressed from a single- and multi-copy 
plasmid (Figure 4.8a). Expression of GFP from a single-copy plasmid resulted in similar 
GFP mRNA levels whether GFP was tagged or untagged. A similar trend was seen when 
GFP was expressed from a multi-copy plasmid. Thus, we conclude that there is no 
correlation between tag translocation efficiency and cargo mRNA levels. Comparing the 
 136 
impact of plasmid copy number, the mean relative expression of GFP expressed from a 
single-copy plasmid was mostly (8 out of 11 samples) within error of GFP expressed 
from a multi-copy plasmid. We attribute this finding to the use of the strong galactose 
promoter (PGal1) for GFP expression.  
To determine if the translocation tags altered the GFP protein expression levels, we 
measured GFP fluorescence of tagged and untagged GFP when expressed from single- 
and multi-copy plasmids using flow cytometry. When GFP was tagged to reach the 
mitochondria, vacuole or peroxisome and expressed from a single-copy plasmid, this 
resulted in a unimodal distribution of GFP fluorescence (Figure 4.8b). However, 
expressing the same constructs from a multi-copy plasmid resulted in a bimodal, wider 
distribution of GFP fluorescence (Figure 4.8c).  Overall, tagged GFP expressed from a 
single-copy plasmid resulted in 90% GFP positive cells, that is cells showing either low, 
medium or high GFP levels. Expression of tagged GFP from a multi-copy plasmid on the 
other hand resulted in 70% GFP positive cells (Figure 4.8d). The single-cell level data is 
in accordance to the visual inspection of cells in the microscopy data.   
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Figure 4.8. Analysis of GFP mRNA levels and GFP protein expression at the single 
cell level. a. Relative GFP mRNA levels of tagged and untagged GFP when 
expressed from single- and multi-copy plasmids. Experiment was performed in 
triplicate and analyzed using the comparative CT method with GFP levels 
normalized to the levels of the housekeeping gene ACT1. Bars represent the range of 
expression. b. Overlaid flow cytometry histograms of live cells by organelle with 
GFP expressed from top: single- or bottom: multi-copy plasmids. c. Variability of 
GFP protein expression levels across cells expressing different tags. Left: The gates 
used to determine cells not expressing GFP (off), and expressing low (L), medium 
(M), or high (H) levels of GFP are shown on the histogram. Right: Percent of live 
cells expressing GFP at different levels.   
4.4 Discussion 
Here, we quantified the translocation efficiencies of three sets of tags for protein 
localization to the S. cerevisiae mitochondrion, vacuole, and peroxisome (Table 
4-1,Table 4-2). For mitochondrial translocation, TCOX4 shows the highest translocation 
efficiency with two different cargo proteins, making it the preferred translocation tag for 
metabolic engineering applications. When choosing vacuolar or peroxisomal tags, TPRC1 
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(~75% of GFP localized to the vacuole) or TLUC (~99% of GFP localized to the 
peroxisomes) are the most suitable choices, respectively. Overall, plasmid copy number 
does not correlate with translocation efficiency of GFP; however, copy number appears 
to slightly affect mKate2 translocation efficiency. This effect could be further studied 
using a weaker promoter than PGal1. Additionally, we show that mRNA levels do not 
significantly vary with translocation tag and are relatively consistent in all GFP-
expressing strains. Finally, we find that, at the protein level, GFP expressed from a 
single-copy plasmid results in a unimodal cell distribution with more GFP positive cells 
than GFP expressed from a multi-copy plasmid. This is attributed to differences in 
plasmid stability and has been observed previously
40
.  
We expect the quantification of translocation efficiency and mRNA levels of 
translocation tags will be a valuable tool to synthetic biologists and metabolic engineers 
looking to localize a single protein or complete pathways to yeast organelles.  Further, 
quantification of the translocation efficiency of these tags will enable researchers to 
calculate the translocation efficiency of their enzymes. It is important to note that every 
situation is different and pathway analysis is first required to determine whether there 
would be a potential advantage to the localization of a protein(s) to a compartment before 
tagging. If the practitioner has determined that there is a potential advantage to localize a 
pathway protein to a compartment (e.g. metabolite precursor, pH, metal concentration, 
toxic intermediates), there should be a resource that the researcher can quickly point to in 
order to identify what tag to use. This manuscript aims to be that resource.  
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Table 4-1. Translocation tag origin 
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Tested 29 amino acids based on the length of the presequence in the human protein.
 
b 


























% GFP positive 
cells 













Mitochondria THSP60 49.2 49.6 0.54 0.56 97.0 87.6 
TCOX4 77.6 79.3 0.38 0.50 99.0 84.0 
TPDA1 48.4 47.7 0.28 1.17 95.1 81.2 
TOLI1 42.3 42.5 0.29 0.36 91.9 46.0 
Vacuole TPHO8 26.3 32.9 0.62 0.60 97.8 91.1 
TAPE1 27.1 31.3 0.19 0.51 98.1 86.7 
TPRC1 78.5 71.7 0.42 0.28 90.4 49.0 
Peroxisome TLUC 99.0 98.5 0.26 0.60 87.7 63.0 
TPOT1 51.5 53.2 0.35 0.86 98.1 91.2 
TCAT 96.2 89.6 1.54 1.40 90.8 70.8 
a
 relative expression levels compared to untagged GFP expressed from a multi-copy 
plasmid, normalized to the housekeeping gene ACT1 
4.5 Materials and Methods 
4.5.1 Confocal Microscopy for GFP 
Viewing and organelle staining protocols were adapted from published protocols
41
 or 
from manufacturer’s instructions.  For mitochondrial tags, overnight cultures of strains 
PPY370, 371, 377, 378, 382, 431, 432, 433  in synthetic complete media lacking leucine 
with 2% glucose (SD(L
-
)) were used to inoculate 5 mL cultures in synthetic complete 
media lacking leucine with 2% galactose buffered with 25 mM potassium phosphate 
(SCgal(L
-
) pH 7) to an OD600 =  0.05. Cultures were incubated at 30°C (250 rpm) for 21 h 
to OD600 = 0.4-1.0. Mitotracker® Red CMXRos (Molecular Probes, 1 mM solution in 
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DMSO) was added to a final concentration of 250nM. Cultures were incubated at 30°C 
(covered with foil, 250 rpm) for 15 min, pelleted, and resuspended in 100 µL phosphate 
buffer (PBS: 135 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4) pH = 7.4 
with 2% glucose. For vacuolar tags, overnight cultures of strains PPY373, 374, 375, 384, 
385, 386 in SD(L
-
) were used to inoculate 5 mL cultures in non-buffered SCgal(L
-
) to an 
OD600 = 0.01. Cultures were incubated at 30°C (250 rpm) for 19 h to OD600 = 0.3-1.0. 
Cells were pelleted and resuspended in 5 mL YPD. 1 mL of cells were pelleted and 
suspended in 50 µL freshly prepared FM4-64 (Molecular Probes) solution (32.9 µM 
FM4-64 in YPD). Samples were incubated at 30°C for 15 min. 1 mL of prewarmed 
(30°C) YPD was added to the samples. Cells were pelleted and washed twice with YPD, 
incubating 30°C 15-60 s between each wash (thermomixer). Samples were incubated at 
30°C (thermomixer) for 60 min, pelleted, and resuspended in 100 µL PBS pH=4.6 with 
2% glucose. For peroxisomal tags, overnight cultures of strains PPY1015, 1016, 372, 
1018, 1019, 383 in SD(L
-
) were used to inoculate 5 mL cultures in SCgal(L
-
) pH 7 to an 
OD600 = 0.08. Cultures were incubated at 30°C (250 rpm) for 19 h to OD600 = 0.6-0.9.  1 
M Tris-Cl pH = 7.5 was added to a final concentration of 10 mM and cells were 
incubated 5 min at 30°C (250 rpm). 1 mL of culture was pelleted and cells were 
resuspended in 50 µL PBS pH = 7.4 with 2% glucose. After induction and staining 
protocols, cells were mounted on poly-L-lysine coated slides and visualized using a 63X 
oil immersion objective lens on a Zeiss 510 UV confocal microscope with an Argon 488 
nm laser, a HeNe 543 nm laser, and FITC and Rhodamine filters. Untagged GFP samples 
were similarly treated as stated above but viewed on a Zeiss LSM 780 with an Argon 488 
nm laser and a HeNe 561 nm laser. 
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4.5.2 Confocal Microscopy for mKate2 
Viewing and organelle staining protocols were adapted from manufacturer’s 
instructions. For mitochondrial tags, overnight cultures of strains PPY1343-1347, 1354-
1358  in SD(L
-
) were used to inoculate 5 mL cultures in SCgal(L
-
) pH 7 to an OD600 = 
0.02. Cultures were incubated at 30°C (250 rpm) for 18 h to OD600 = 0.3-1.3. 
Mitotracker® Green (Molecular Probes, 1 mM solution in DMSO) was added to a final 
concentration of 200 nM. Cultures were incubated at 30°C (covered with foil, 250 rpm) 
for 45 min, pelleted, and resuspended in 200 µL PBS pH = 7.4 with 2% glucose. For 
vacuolar tags, overnight cultures of strains PPY1347, 1351-1353, 1358, 1362-1364 in 
SD(L
-
) were used to inoculate 5 mL cultures in non-buffered SCgal(L
-
) to an OD600 = 
0.02. Cultures were incubated at 30°C (250 rpm) for 16 h to OD600 = 0.2-0.5. Cells were 
pelleted and resuspended in 5 mL PBS pH=7.4 with 2% glucose. Yeast Vacuole Marker 
MDY-64 (Molecular Probes, 50 mM solution in DMSO) was added to a final 
concentration of 10 µM. Samples were incubated at room temperature for 3-5 min. Cells 
were pelleted and resuspended in 200 µL PBS pH = 7.4 with 2% glucose. For 
peroxisomal tags, overnight cultures of strains PPY1347-1350,1358-1361 in SD(L
-
) were 
used to inoculate 5 mL cultures in SCgal(L
-
) pH 7 to an OD600 = 0.02. Cultures were 
incubated at 30°C (250 rpm) for 17 h to OD600 = 0.3-0.7.  1 M Tris-Cl pH = 7.5 was 
added to a final concentration of 10 mM and cells were incubated 5 min at 30
o
C (250 
rpm). 1 mL of culture was pelleted and cells were resuspended in 50-100 µL PBS pH = 
7.4 with 2% glucose. After induction and staining protocols, cells were mounted on poly-
L-lysine coated slides and mKate2 was visualized using a 63X oil immersion objective 
lens on a Zeiss LSM 780 confocal microscope with an Argon 458 nm laser and a HeNe 
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594 nm laser. Some staining was unsuccessful and therefore mKate2 data was used for 
qualitative purposes only. 
4.5.3 Quantification of GFP Localization 
GFP localization was quantified using ImageJ software
42
. Using the rhodamine 
channel image, organelles were manually outlined and saved as individual regions of 
interest (ROIs). Using the bright field image, an area in the cytosol was saved as a cytosol 
ROI. Mean fluorescence intensity was measured for each ROI in the FITC channel 
image. For each tag, 15-50 GFP positive cells with average fluorescence were analyzed 
with each cell having 1-5 ROIs corresponding to separate organelles. For each cell, the 
mean intensity for organelle ROIs and cytosol ROIs were calculated and added together 
to get a total intensity. The organelle intensity was divided by the total intensity and 
multiplied by 100 to obtain the percent of GFP localized to the organelle. Percent of GFP 
localized to an organelle for at least 15 cells were used to obtain the average and standard 
deviation. For peroxisomal tags, the peroxisome was not chemically labeled, thus no 
rhodamine channel signal was acquired; ROIs were chosen based on apparent 
localization using the FITC channel and bright field image. 
𝑀𝑒𝑎𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑜𝑟𝑔𝑎𝑛𝑒𝑙𝑙𝑒𝑠 + 𝑀𝑒𝑎𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑐𝑦𝑡𝑜𝑠𝑜𝑙 = 𝑀𝑒𝑎𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑡𝑜𝑡𝑎𝑙 
𝑀𝑒𝑎𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑜𝑟𝑔𝑎𝑛𝑒𝑙𝑙𝑒𝑠
𝑀𝑒𝑎𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑡𝑜𝑡𝑎𝑙
∗ 100 = 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 
 
4.5.4 mRNA Quantification 
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Overnight cultures of strains in SD(L-) were used to inoculate 5 mL cultures of 
SCgal(L-) to an OD600 = 0.01. Cultures were incubated for 19 h at 30°C (250 rpm) to 
OD600 = 0.2-0.9. Cultures were pelleted and total RNA was extracted using a RNeasy 
Mini kit (Qiagen). RNA quantity was measured using NanoDrop Lite and samples were 
stored at -80°C. 1 µg of total RNA was taken from each strain and converted into cDNA 
using a QuantiTect Reverse Transcription kit (Qiagen). RT-PCR reactions were set up 
using a QuantiTect SYBR Green PCR kit (Qiagen) with 3 μL cDNA (cDNA from 150 ng 
mRNA) per strain. Triplicate reactions were set up for each strain. Amplification was 
completed using a StepOnePlus Real-time PCR system (Applied Biosystems) with 
primers AMEGFP-F/AMEGFP-R and AMEACT-F/AMEACT-R. GFP expression was 
normalized to reference gene ACT1, a gene that encodes actin, and relative expression 
was compared to untagged GFP expressed from a multi-copy plasmid determined using 
the comparative CT method
43
.     
∆𝐶𝑇𝑠𝑎𝑚𝑝𝑙𝑒 = 𝑎𝑣𝑔𝐶𝑇𝐺𝐹𝑃 − 𝑎𝑣𝑔𝐶𝑇𝑎𝑐𝑡𝑖𝑛 
∆∆𝐶𝑇 = ∆𝐶𝑇𝑠𝑎𝑚𝑝𝑙𝑒 − ∆𝐶𝑇𝑢𝑛𝑡𝑎𝑔𝑔𝑒𝑑 𝐺𝐹𝑃 𝑚𝑢𝑙𝑡𝑖−𝑐𝑜𝑝𝑦 
2−∆∆𝐶𝑇 = 𝑀𝑒𝑎𝑛 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝐺𝐹𝑃 𝑐𝑜𝑚𝑝𝑎𝑟𝑒𝑑 
𝑡𝑜 𝑢𝑛𝑡𝑎𝑔𝑔𝑒𝑑 𝐺𝐹𝑃 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑓𝑟𝑜𝑚 𝑎 𝑚𝑢𝑙𝑡𝑖 − 𝑐𝑜𝑝𝑦 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 
2−(∆∆𝐶𝑇±𝑠) = 𝑅𝑎𝑛𝑔𝑒 𝑜𝑓 𝑓𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝐺𝐹𝑃 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙 
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜 𝑢𝑛𝑡𝑎𝑔𝑔𝑒𝑑 𝐺𝐹𝑃 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑒𝑑 𝑓𝑟𝑜𝑚 𝑎 𝑚𝑢𝑙𝑡𝑖 − 𝑐𝑜𝑝𝑦 𝑝𝑙𝑎𝑠𝑚𝑖𝑑 
𝑠 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 ∆𝐶𝑇𝑠𝑎𝑚𝑝𝑙𝑒 
 
4.5.5 Protein Expression Analysis Using Flow Cytometry 
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Overnight cultures of strains in SD(L-) were used to inoculate 5 mL cultures of 
SCgal(L-) to an OD600 = 0.01. Cultures were incubated at 30°C (250 rpm) to OD600 = 0.2-
0.8 and diluted 10-fold with SCgal(L-) media. GFP fluorescence for 10,000 cells was 
measured using a Guava easyCyte HT (Millipore). Data was analyzed using FlowJo. 
First, we gated for live cells (by forward and side scatter), selecting >86% of cells in all 
cases (Figure 4.9). Then we gated for GFP positive cells (Figure 4.8). 
 
Figure 4.9. Live cell gating for flow cytometry analysis. To account for dead and 
outlier cells, we gated samples using forward- and side-scatter. An example gate is 
shown in black. In all cases, ≥ 86% of cells were chosen in the gated population. 
4.5.6 Plasmid Construction 
To construct pAME3s-5s, and 9, eGFP was amplified from pEGFP using primers 
AME440/AME103, AME440/AME121, AME440/AME122, or AME133/AME124, 
respectively, and cloned into pESC-Leu2 at BamHI/HindIII. To construct pAME7-8 and 
pAME10-12, signal tags were amplified from pCR2.1-AME_1 using primers 
AME108/AME109 (THSP60), AME110/AME111 (TCOX4), AME114/AME115 (TPHO8), 
AME116/AME117 (TAPE1), or AME118/AME119 (TPRC1) and cloned into pAME3 at 
BamHI/NcoI. To construct pAME14 and pAME15, signal tags were amplified from 
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pCR2.1-tags2.0 using primers AME155/AME156 (TPDA1) or AME157/AME158 (TOLI1), 
respectively, and cloned into pAME3 at BamHI/NcoI. Inserts were sequenced with 
primers AME104/AME105. 
Vectors for pAME92-95, and 99-102 were amplified using respective templates and 
primers (template/primer/primer): pAME7/AME231/AME484 (pAME92), 
pAME8/AME231/AME232 (pAME93), pAME14/AME231/AME489 (pAME94), 
pAME15/AME231/AME490 (pAME95), pAME9/AME231/AME485 (pAME99), 
pAME10/AME231/AME486 (pAME100), pAME11/AME231/AME487 (pAME111), 
pAME12/AME231/AME488 (pAME112). Amplified vectors were digested with DpnI 
and PCR purified. Vectors for pAME96 and pAME97-98 were created via digestion of 
pAME3s with BamHI/HindIII or BamHI/SacII, respectively. mKate2 was amplified from 
pKM1032 with primers AME491/AME493 (pAME92, 94-95, 99-102), 
AME494/AME493 (pAME93), AME492/AME493 (pAME96), AME492/AME496 
(pAME97), or AME492/AME495 (pAME98) and cloning into their respective vectors. 
Inserts were sequenced with primer AME104. 
The region between terminators tADH1 and tCYC1 was amplified from pAME3s-5s, 
7-12, 14-15, and 92-102 using primers AME184/AME185 and cloned into pRS415 at 
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CHAPTER 5. Conclusions and Future Direction 
5.1 General Conclusions 
The work presented in this thesis represents the first production of a modified 
monoterpene indole alkaloid in the yeast Saccharomyces cerevisiae. Further, it serves as 
a resource to the synthetic biology community through the unique analysis of current 
pharmaceuticals put forth in chapter 1 as well as through the analysis of translocation tag 
efficiencies in chapter 4. Additionally, the development of a medium-throughput GPCR-
based sensing assay to sense a microbially-produced chemical is likely to mirror 
optimizations that would be needed to develop similar sensors in the future. 
5.2 Future Directions 
5.2.1 Bioproduction of Other Alkaloid Families 
While the work in this thesis focused on microbial production of a modified 
monoterpene indole alkaloid (MIA), similar work can be done involving other alkaloid 
families. Benzylisoquinoline alkaloids (BIAs) have been the subject of a majority of 
microbial metabolic engineering works in the field due to the vast knowledge of their 
biosynthetic pathways
1,2
. Increasing works have involved other families including 
ergots
3-6
 and more recently xanthines
7
. Analyses such as the one showcased in chapter 1, 
which focused on alkaloids derived from tyrosine and tryptophan, can be done on other 
families of alkaloids with different biosynthetic origins or on other classes of natural 
products in general. This type of analysis would supply researchers with an application-
based roadmap for target identification. Once beneficial targets are determined, metabolic 
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engineering, pathway elucidation, and protein engineering can be used to develop 
microbes to produce the products of interest in a rapid and renewable fashion. 
5.2.2 Bioproduction of Advanced MIAs 
The work in chapter 2 resulted in the microbial production of hydroxystrictosidine, a 
hydroxylated early intermediate in the monoterpene indole alkaloid (MIA) pathway 
leading to camptothecin. Advancement of hydroxystrictosidine through the camptothecin 
pathway would result in hydroxycamptothecin, which can potentially accelerate the 
semisynthesis of current anti-cancer drugs topotecan and irinotecan as well as novel anti-
cancer agents. Modified MIA precursors have been shown to convert to their 
corresponding modified alkaloids in plant cultures, which is promising for microbial 
production of compounds such as hydroxycamptothecin once the downstream plant 
enzymes are expressed in yeast. A key challenge that remains regarding this goal is 
biosynthetic pathway elucidation, as no further downstream enzymes in the camptothecin 
pathway are currently known and very few downstream enzymes are known in other 
advanced MIA pathways. I believe that the most significant development in the area of 
microbial production of advanced MIAs, and other natural products, will be rapid 
pathway elucidation. With increasing advances in synthetic biology and metabolic 
engineering tools and technologies, I am confident that once this knowledge is obtained 
there will be a substantial increase in the microbial production of useful modified 




5.2.3 Screening of Serotonin-Producer Libraries 
With the engineering of a serotonin-producing microbe (chapter 2) and a serotonin-
sensing microbe (chapter 3), the stage is set to rapidly engineer a better serotonin-
producer. A variety of approaches can be used to create libraries of producer mutants, 
including random or rational designs targeted at key enzymes in the pathway, competing 
enzymes, precursor production, or product transport. Chapter 3 established a medium-
throughput assay that can rapidly screen these producer mutants using a GPCR-based 
sensor. Once positive hits are obtained, serotonin levels can be verified and quantified 
using LC/MS. Improved serotonin producers can then be used to engineer improved 
alkaloid producers. 
5.2.4 Expansion of Signal Tag Studies 
The work in chapter 4 focused on quantifying the translocation efficiencies of a 
subset of translocation tags to three organelles (mitochondria, vacuole, and peroxisome). 
This study can be expanded to investigate larger suites of tags as well as other organelle 
targets, such as the nucleus. It would be interesting to examine further the context 
dependency of various tags, such as that seen for mitochondrial tags in chapter 4. The 
results and techniques in chapter 4 and expanded studies could additionally aid in the 
construction of improved signal tags. 
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APPENDIX A. Tables of Plasmids 
Table A-1. Plasmids used in chapter 2 































F. Storici lab 
PPY39 pESC-Leu2 




PPY40 pAME3 pESC-PGAL1-eGFP-Leu2 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY154 pCR2.1_HGTPCH 
Codon optimized* 
GTPCH from H. sapiens  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY156 pCR2.1_MaGTPCH 
Codon optimized* 
GTPCH from M.alpinas  
Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
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Table A-1. continued 




Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY171 pCR2.1_MaPTS 
Codon optimized* PTPS 
from M. alpinas  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY172 pCR2.1_SPTS 
Codon optimized* PTPS 
from S. salar  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY173 pCR2.1_RubPTS 
Codon optimized* PTPS 
from S. ruber  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY174 pCR2.1_PmPTS 
Codon optimized* PTPS 
from P. mikurensis  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY181 pCR2.1_MaSR 
Codon optimized* SR 
from M. alpina with N-
terminal His6-tag  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY182 pCR2.1_PseudoSR 
Codon optimized* SR 
from T. pseudonana with 
N-terminal His6-tag 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 





Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
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Table A-1. continued 





Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY242 pAME29 pESC-PGAL1-eGFP-Trp1 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY243 pAME30 pESC-PGAL1-eGFP-His3 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY338 pSS102 
pESC-Ura3 with 
divergent PHXT7/ PTEF1 
promoter 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY435 pCR2.1_DHPR 
Codon optimized* 
DHPR from H. sapiens  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY442 pSS42 
Codon optimized (for E. 




Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
Sequence from 
Bernhardt et al. (2010) 






Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY444 pSS44 
Codon optimized* TPH 
from H. sapiens  
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
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Table A-1. continued 
Strain # Plasmid Name Description Source 
PPY465 pSS48 
Codon optimized* PCD 
from H. sapiens  
Chapter 2;  
Ehrenworth et al. (2015) ACS 





Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY538 pSS61 pESC-PGAL1-STR-Ura3 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY539 pSS62 
Codon optimized* DDC 
from S. scrofa 
Chapter 2;  
Ehrenworth et al. (2015) ACS 





Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY563 pSS64 
Codon optimized* TH 
from M. musculus  
Chapter 2;  
Ehrenworth et al. (2015) ACS 





Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY574 pSS68 pESC-PGAL10-TH-Ura3 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY630 pSS70 pESC-PGAL1-TPH-Ura3 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
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Table A-1. continued 




Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 





Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 





Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY723 pAME63 pESC-PGAL10-DDC-Leu2 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
*“Codon optimized” references commercial codon optimization for S. cerevisiae unless 
otherwise noted (Operon) 
 
Table A-2. Plasmids used in chapter 3  
Strain # Plasmid Name Description Source 
---- ---- 
DNA fragments of yeast 
codon optimized 5-HT1a, 5-
HT1d, 5-HT2b,5-HT4, 5-HT5a, 
5-HT6, and ZsGreen 
Life Technologies 
PPY2 pmCherry 
Vector carrying mCherry 
fluorescent protein 
Y. Chenoff  lab 
PPY34 pESC-His3 
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Table A-2. continued 
Strain # Plasmid Name Description Source 
PPY35 pESC-Ura3 















pESC-His3 with divergent 
PTEF1/PADH1 promoters 
Mukherjee et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 




Chapter 2;  
Ehrenworth et al. (2015) ACS 





Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY586 pKM586 pRS415- PFIG1-eGFP-Leu2 
Mukherjee et al. (2015) ACS 
Synth. Biol. 4, 1261-1269 
PPY630 pSS70 pESC-PGAL1-TPH-Ura3 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
PPY1191 pTMC14 pESC-PTEF1-5-HT2b-His3 Chapter 3 
PPY1192 pTMC18 pESC-PTEF1-5-HT4-His3 Chapter 3 
PPY1193 pTMC22 pESC-PTEF1-5-HT5a-His3 Chapter 3 





PPY1421 pAME142 pESC-PTEF1-5-HT1d-His3 Chapter 3 
PPY1422 pAME144 pESC-PTEF1-5-HT1a-His3 Chapter 3 
PPY1443 pAME143 pRS415- PFIG1-ZsGreen-Leu2 Chapter 3 
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Table A-3. Plasmids used in chapter 4 









tags THSP60, TCOX4, TPHO8, 
TAPE1, and TPRC1 
Eurofins Operon 
PPY38 pEGFP 
Enhanced Green Fluorescent 
Protein 
F. Storici lab 
PPY39 pESC-Leu2 




PPY40 pAME3 pESC-PGAL1-eGFP-Leu2 
Chapter 2;  
Ehrenworth et al. (2015) ACS 













































Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
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Table A-3. continued 





















































Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY931 pAME3s pESC-PGAL1-eGFP-Leu2 
Chapter 4; 












Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
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Table A-3. continued 
Strain # Plasmid Name Description Source 
PPY934 pMH3s pRS415-PGAL1-eGFP-Leu2 
Chapter 4; 








































Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY1047 pAME96 pESC-PGAL1-mKate2-Leu2 
Chapter 4; 
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Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY1063 pAME107 pRS415-PGAL1-mKate2-Leu2 
Chapter 4; 
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APPENDIX B. Tables of Strains 
Table B-1. Yeast strains used in chapter 2 
Strain # Name Description Source 
PPY11 W303 
Saccharomyces cerevisiae MATa 
ade2-1 ura3-1 his3-11 trp1-1 







S. cerevisiae W303 with a T190G 
mutation in Ade2 gene 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME17, pAME22PCD, 
pAME26DHPR, and pSS68 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS66, pAME22PCD, 
pAME26DHPR, and pSS70 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS66, pAME22PCD, 
pAME26DHPR, and pSS71 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS66, pAME22PCD, 
pAME26DHPR, and pSS68 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME17, pAME22, pAME26, 
and pSS68 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME56 and pAME57 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS66, pAME22, pAME26, and 
pSS70 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS66, pAME22, pAME26, and 
pSS68 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME56, pAME57, and 
pAME58 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
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 transformed with 
pAME56, pAME57, and pESC-
Ura3 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME57 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME55, pAME54, and 
pAME53 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME22, and pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME22, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME22, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME22, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME23, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME23, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME23, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME24, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME24, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
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W303 transformed with 
pAME17, pAME24, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME25, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME25, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME25, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME22, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME22, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME22, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME23, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME23, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME25, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME24, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME24, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
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W303 transformed with 
pAME19, pAME25, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME25, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME25, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME22, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME22, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME22, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME23, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME23, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME23, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME24, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME24, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME24, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
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W303 transformed with 
pAME20, pAME25, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME25, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME20, pAME25, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME17, pAME22, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME17, pAME22, and 
pAME52 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME17, pAME54, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME55, pAME22, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME55, pAME54, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME55, pAME22, and 
pAME53 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME17, pAME54, and 
pAME53 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME23, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME24, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
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W303 transformed with 
pAME18, pAME24, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME24, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME25, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME18, pAME25, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME22, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME22, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME22, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME23, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME23, and 
pAME27 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME23, and 
pAME28 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME19, pAME24, and 
pAME26 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with pAME3, 
pAME29, and pAME30 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
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 transformed with 
pAME64 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pESC-Ura3 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME22, pAME26, and pSS68 
Chapter 2;  
Ehrenworth et al. (2015) ACS 




W303 transformed with 
pAME17, pAME22, pAME26, 
and pSS68 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS68, pESC-Leu2, pESC-His3, 
and pESC-Trp1 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME63, pSS68, pESC-His3, 
and pESC-Trp1 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pAME63, pSS70, pESC-His3, 
and pESC-Trp1 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






Chapter 2;  
Ehrenworth et al. (2015) ACS 






Chapter 2;  
Ehrenworth et al. (2015) ACS 






Chapter 2;  
Ehrenworth et al. (2015) ACS 






Chapter 2;  
Ehrenworth et al. (2015) ACS 






Chapter 2;  
Ehrenworth et al. (2015) ACS 
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Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS66, pAME22, pAME26, and 
pSS71 
Chapter 2;  
Ehrenworth et al. (2015) ACS 
Synth. Biol. 4, 1295-1307 
 
Table B-2. Yeast strains used in chapter 3. 
Strain # Name Description Source 
PPY140 W303-3Δ 
Saccharomyces cerevisiae 
MATa ade2-1 ura3-1 his3-11 
trp1-1 leu2-3 leu2-112 can1-
100 Δfar1, Δsst2, Δste2 
Mukherjee et al. (2015) ACS 






S. cerevisiae W303 with a 
T190G mutation in Ade2 gene 
Chapter 2;  
Ehrenworth et al. (2015) ACS 






 transformed with 
pSS66, pAME22, pAME26, 
and pSS70 
Chapter 2;  
Ehrenworth et al. (2015) ACS 










































PPY568 carrying pESC-His3, 






















Table B-3. Yeast strains used in chapter 4 
Strain # Name Description Source 
PPY11 W303 
Saccharomyces cerevisiae MATa 
ade2-1 ura3-1 his3-11 trp1-1 leu2-3 
leu2-112 can1-100 
ATCC® 20835 
PPY370 W303-7 W303 transformed with pAME7 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY371 W303-8 W303 transformed with pAME8 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY372 W303-9 W303 transformed with pAME9 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY373 W303-10 W303 transformed with pAME10 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY374 W303-11 W303 transformed with pAME11 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY375 W303-12 W303 transformed with pAME12 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY377 W303-14 W303 transformed with pAME14 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY378 W303-15 W303 transformed with pAME15 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY382 W303-M7 W303 transformed with pMH7 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY383 W303-M9 W303 transformed with pMH9 
Chapter 4; 





W303 transformed with pMH10 
Chapter 4; 





W303 transformed with pMH11 
Chapter 4; 
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W303 transformed with pMH12 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY431 W303-M8 W303 transformed with pMH8 
Chapter 4; 





W303 transformed with pMH14 
Chapter 4; 





W303 transformed with pMH15 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY1014 W303-3s W303 transformed with pAME3s 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY1015 W303-4s W303 transformed with pAME4s 
Chapter 4; 
Ehrenworth et al. (2017) 
Biotechnol. Bioeng. 
PPY1016 W303-5s W303 transformed with pAME5s 
Chapter 4; 





W303 transformed with pMH3s 
Chapter 4; 





W303 transformed with pMH4s 
Chapter 4; 





W303 transformed with pMH5s 
Chapter 4; 





W303 transformed with pESC-
Leu2 
Chapter 4; 





W303 transformed with pRS415 
Chapter 4; 





W303 transformed with pAME92 
Chapter 4; 
Ehrenworth et al. (2017) 
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W303 transformed with pAME93 
Chapter 4; 





W303 transformed with pAME94 
Chapter 4; 





W303 transformed with pAME95 
Chapter 4; 





W303 transformed with pAME96 
Chapter 4; 





W303 transformed with pAME97 
Chapter 4; 





W303 transformed with pAME98 
Chapter 4; 





W303 transformed with pAME99 
Chapter 4; 





W303 transformed with pAME100 
Chapter 4; 





W303 transformed with pAME101 
Chapter 4; 





W303 transformed with pAME102 
Chapter 4; 





W303 transformed with pAME103 
Chapter 4; 





W303 transformed with pAME104 
Chapter 4; 





W303 transformed with pAME105 
Chapter 4; 
Ehrenworth et al. (2017) 
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W303 transformed with pAME106 
Chapter 4; 





W303 transformed with pAME107 
Chapter 4; 





W303 transformed with pAME108 
Chapter 4; 





W303 transformed with pAME109 
Chapter 4; 





W303 transformed with pAME110 
Chapter 4; 





W303 transformed with pAME111 
Chapter 4; 





W303 transformed with pAME112 
Chapter 4; 





W303 transformed with pAME113 
Chapter 4; 




APPENDIX C. Table of Primers 
Table C-1. Table of primers used in this work 
Name Sequence (5' -> 3') 
Chapters 
used in 
ACT1-F TTGGATTCCGGTGATGGTGT 2 





AME104 CACTTTAACTAATACTTTCAAC 2; 4 























































Table C-1. continued 
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AME161 CATAACATCCAATTAGTGCAA 2 
AME162 AATACTTCTTCTTCCTAAAAG 2 
AME163 CCATCACTCAGTAAAGAAGC 2 













AME168 GGTAAAGTTATTTTAGTTACAG 2 















Table C-1. continued 







AME229 ACGTATCTACCAACGATTTG 2; 3 
AME230 GTATATGGATATGTATATGGTG 2 
AME231 AAGCTTGGTACCGCGGC 4 




























AME365 GGTCGCTTTTTGATTAAAATTAAAAAAACTTT 2 









AME369 TTTGCGAACACTTTTATTAATTC 2 















Table C-1. continued 















































AME394 GTAATACGACTCACTA 2 
AME395 ACTAGTATCGATGGATTACAA 2 
AME396 CATTTGCAGCTATTGTAAAATA 2 










AME441 CACAAGGGTCCATAACAGC 2 
AME442 ACGGTCATAATTACAAGGTTG 2 
AME443 CGATGAAATGGTCACCGTG 2 
AME444 GACAGACCGATCACCGAAT 2 
AME445 CTGGCAAGAAGCTAGATCC 2 
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Table C-1. continued 
Name Sequence (5' -> 3') 
Chapters 
used in 
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Table C-1. continued 











AMEACT-F TTCTGAGGTTGCTGCTTTGG 4 
AMEACT-R ACCGACGATAGATGGGAAGAC 4 
AMEGFP-F TCAAGATCCGCCACAACATC 4 
AMEGFP-R GTGCTCAGGTAGTGGTTGTC 4 
MH100 ACGTTGTAAAACGACGGCC 2; 4 
MH101 CTATGACCATGATTACGCC 2; 4 













































APPENDIX D. DNA Sequences 
DNA synthesized for chapter 2: 
 


















































































































































































































































Ophiorrhiza pumila Strictosidine synthase (6x-His tag underlined) (Q94LW9) (Sequence 





















DNA synthesized for chapter 3: 

















































































































Homo sapiens 5-Hydroxytryptamine receptor 6 (P50406) 
ATGGTTCCAGAACCAGGTCCAACTGCTAACTCTACTCCAGCTTGGGGTGCTGGTCCACC
ATCTGCTCCAGGAGGTTCTGGTTGGGTTGCTGCTGCTTTGTGTGTTGTTATTGCTTTAA
CTGCTGCAGCTAATTCTCTATTGATTGCTCTAATTTGTACTCAACCAGCTTTGAGAAAC
ACTTCTAACTTCTTCTTGGTTTCATTGTTCACTTCTGATTTGATGGTTGGTTTGGTTGT
CATGCCACCAGCTATGTTGAACGCTTTGTACGGTAGATGGGTTTTGGCTAGAGGTTTGT
GTTTGTTATGGACTGCTTTCGATGTTATGTGTTGTTCTGCTTCTATCTTGAACTTGTGT
TTGATTTCTTTGGATAGATACTTGTTGATTTTGTCTCCTTTGAGATACAAGTTAAGAAT
GACTCCATTGAGAGCATTAGCTCTAGTTTTGGGAGCTTGGTCTTTGGCTGCTTTGGCAT
 194 
CTTTCTTACCTTTGCTATTGGGTTGGCATGAATTAGGTCATGCTAGACCACCAGTTCCA
GGTCAATGTAGATTGTTAGCTTCTTTACCATTTGTCTTGGTTGCTTCCGGTTTGACTTT
CTTCTTGCCATCTGGTGCTATTTGTTTCACTTACTGTAGAATTTTGTTAGCTGCTAGAA
AACAAGCTGTTCAAGTTGCTTCTTTAACTACTGGTATGGCTTCTCAAGCATCTGAAACT
TTACAAGTTCCAAGAACTCCAAGACCAGGTGTTGAATCTGCTGATTCTAGAAGATTGGC
TACTAAACATTCTAGAAAGGCTTTGAAAGCATCCTTAACTTTGGGTATCTTGTTAGGTA
TGTTCTTTGTTACTTGGTTACCATTCTTTGTTGCTAACATTGTTCAAGCTGTTTGTGAT
TGTATTTCTCCAGGTTTGTTTGATGTTTTGACTTGGTTAGGATATTGTAATTCTACTAT
GAATCCAATCATCTATCCATTGTTTATGAGAGATTTCAAGAGAGCTTTAGGTAGATTCT
TGCCTTGTCCAAGATGTCCAAGAGAAAGACAAGCATCTTTGGCTTCTCCATCTTTGAGA
ACTTCTCATTCTGGTCCAAGACCTGGTTTGTCTTTACAACAAGTTTTGCCATTACCATT
ACCACCAGATAGTGATTCAGATTCTGATGCTGGTTCAGGTGGTTCATCTGGTTTGAGAT
TAACTGCTCAATTGTTGTTACCAGGTGAAGCTACTCAAGATCCTCCTTTGCCAACAAGA
GCTGCCGCTGCAGTTAATTTCTTCAACATTGATCCTGCTGAACCTGAATTGAGACCACA
TCCATTAGGTATTCCAACTAATTAA 
ZsGreen 
ATGGCTCAATCTAAGCATGGTTTGACTAAGGAAATGACTATGAAGTACAGAATGGAAGG
TTGTGTTGACGGTCATAAGTTCGTTATCACTGGTGAAGGAATTGGTTATCCATTCAAAG
GTAAGCAGGCTATCAACTTGTGTGTTGTTGAAGGTGGTCCATTGCCATTCGCTGAAGAC
ATCTTGTCTGCTGCTTTCATGTACGGTAACAGAGTCTTCACTGAATACCCACAAGACAT
TGCTGATTACTTCAAGAACTCTTGTCCAGCTGGTTACACTTGGGATAGATCCTTCTTGT
TTGAAGATGGTGCTGTTTGTATCTGTAATGCTGATATCACTGTTTCTGTTGAAGAAAAC
TGTATGTATCATGAATCTAAGTTCTATGGTGTCAACTTCCCAGCTGATGGTCCAGTTAT
GAAGAAGATGACTGATAACTGGGAACCATCTTGTGAAAAGATCATTCCAGTTCCAAAGC
AAGGTATCTTGAAAGGTGATGTTTCTATGTACTTGCTATTGAAAGATGGTGGTAGATTG
AGATGTCAATTCGATACTGTCTACAAAGCTAAGTCTGTTCCAAGAAAGATGCCAGATTG
GCATTTCATTCAACATAAGTTGACTAGAGAAGATAGATCTGATGCTAAGAATCAAAAGT
GGCATCTAACTGAACATGCTATTGCTTCTGGTTCTGCTTTGCCATAA 
